REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested. Pursuant to 37 CFR § 1.121, attached as Appendix A is a Version With Markings to Show Changes Made.

Interactions between bacterial pathogens and their plant hosts generally fall into two categories: (1) compatible (pathogen-host), leading to intercellular bacterial growth, symptom development, and disease development in the host plant; and (2) incompatible (pathogen-nonhost), resulting in the hypersensitive response, a particular type of incompatible interaction occurring, without progressive disease symptoms. During compatible interactions on host plants, bacterial populations increase dramatically and progressive symptoms occur. During incompatible interactions, bacterial populations do not increase, and progressive symptoms do not occur.

The hypersensitive response is a rapid, localized necrosis that is associated with the active defense of plants against many pathogens. The hypersensitive response elicited by bacteria is readily observed as a tissue collapse if high concentrations ($\geq 10^7$ cells/ml) of a limited host-range pathogen like *Pseudomonas syringae* or *Erwinia amylovora* are infiltrated into the leaves of nonhost plants (necrosis occurs only in isolated plant cells at lower levels of inoculum). The capacities to elicit the hypersensitive response in a nonhost and be pathogenic in a host appear linked. These pathogens also cause physiologically similar, albeit delayed, necroses in their interactions with compatible hosts. Furthermore, the ability to produce the hypersensitive response or pathogenesis is dependent on a common set of genes, denoted *hrp*. Consequently, the hypersensitive response may hold clues to both the nature of plant defense and the basis for bacterial pathogenicity.

The *hrp* genes are widespread in Gram-negative plant pathogens, where they are clustered, conserved, and in some cases interchangeable. Several *hrp* genes encode components of a protein secretion pathway similar to one used by *Yersinia, Shigella*, and *Salmonella* spp. to secrete proteins essential in animal diseases. In *E. amylovora, P. syringae*, and *P. solanacearum*, *hrp* genes have been shown to control the production and secretion of glycine-rich, protein elicitors of the hypersensitive response.

The first of these proteins was discovered in *E. amylovora* Ea321, a bacterium that causes fire blight of rosaceous plants, and was designated harpin. Mutations in the encoding *hrpN* gene revealed that harpin is required for *E. amylovora* to elicit a hypersensitive response in nonhost tobacco leaves and incite disease symptoms in highly

susceptible pear fruit. The *P. solanacearum* GMI1000 PopA1 protein has similar physical properties and also elicits the hypersensitive response in leaves of tobacco, which is not a host of that strain. However, *P. solanacearum popA* mutants still elicit the hypersensitive response in tobacco and incite disease in tomato. Thus, the role of these glycine-rich hypersensitive response elicitors can vary widely among Gram-negative plant pathogens.

Other plant pathogenic hypersensitive response elicitors have been isolated, cloned, and sequenced. These include: *Erwinia chrysanthemi*; *Erwinia carotovora*; *Erwinia stewartii*; and *Pseudomonas syringae* pv. *syringae*.

The present invention seeks to identify fragments of hypersensitive response elicitor proteins or polypeptides, which fragments do not elicit a hypersensitive response but are active when utilized in conjunction with plants.

The objection to the Oath/Declaration is respectfully traversed in view of the new "Combined Declaration for Patent Application and Power of Attorney" submitted herewith.

objection remains

The objection to the specification based on informalities is respectfully traversed in view of the amendments to the specification.

withdrawn

The objection of the information disclosure statement filed by applicants on February 4, 2000, and received by the United States Patent and Trademark Office ("USPTO") on February 9, 2000, for failure to comply with 37 CFR §§ 1.97 and 1.98 and with MPEP § 609, is respectfully traversed. The USPTO has not considered references 1-11, 13, 15-33, 35-105, and 108-163 listed in the PTO Form-1449, which form was submitted with the information disclosure statement dated February 4, 2000, on the ground that these references are missing from the present application. Based on review of its files for this case, applicants have concluded that copies of all of the identified references were indeed forwarded to the USPTO on February 4, 2000. Before incurring the significant cost of re-copying the 158 references at issue, applicants respectfully request that the USPTO take another look for the references. If the USPTO still cannot find the references, applicants request that they be given an opportunity to forward additional copies of the references to the USPTO for consideration, without the need to pay additional fees, and that such consideration be granted.

check for references in 10th floor

The rejection of claims 1-9 and 30-38 under 35 U.S.C. § 112 (1st para.) for lack of adequate written description is respectfully traversed in view of the above amendments and the following remarks.

The USPTO has also taken the position that the present application does not adequately describe the claimed genus of fragments of hypersensitive response elicitor proteins or polypeptides which do not elicit a hypersensitive response but which have other activities in plants. Applicants respectfully disagree. On page 32, line 3, through page 34, line 2, and in Examples 1-17, the present application clearly identifies suitable fragments of the claimed genus and provides ample guidance as to how to produce other suitable fragments of the genus. For example, the present application identifies as suitable fragments the C-terminal, N-terminal, and internal fragments of the amino acid sequence of SEQ ID NO: 23, which sequence corresponds to the *Erwinia amylovora* hypersensitive response elicitor (page 32, lines 27-32). More specifically, the C-terminal fragments are identified as spanning amino acid residues 169-403, 210-403, 267-403, or 343-403 of SEQ ID NO: 23 (page 32, line 32, through page 33, line 2). The internal fragments are identified as spanning amino acid residues 105-179, 137-166, 121-150, or 137-156 of SEQ ID NO: 23 (page 33, lines 2-4). The present application also identifies as a suitable fragment of the claimed genus, the fragment containing amino acid residues 190-294 of the amino acid sequence of SEQ ID NO: 31, which sequence corresponds to the *Pseudomonas syringae* pv. *syringae* hypersensitive response elicitor (page 33, lines 6-9). As yet a further example of a suitable fragment of the claimed genus, the present application identifies the peptide having an amino acid sequence corresponding to SEQ ID NO: 39, which peptide is derived from the hypersensitive response eliciting glycoprotein of *Phytophthora megasperma* (page 33, lines 11-14).

The present application also provides adequate disclosure to allow one of ordinary skill in the art to determine and produce other fragments belonging to the claimed genus (page 32, line 3, through page 34, line 2, and Examples 1-17). For example, suitable fragments can be produced using subcloning techniques well known in the art, as described on page 32, lines 6-10, and in Examples 1-16 of the present application. Alternatively, the present applications discloses the use of proteolytic enzymes to produce fragments of the claimed genus, which techniques are well known in the art (page 32, lines 11-16). The present application also teaches the use of polymerase chain reaction and specific primers to synthesize the fragments of the claimed genus (page 32, lines 17-22). Further, suitable fragments of the present invention may be made using chemical synthesis techniques well known in the art, as described in the present application on page 32, lines 22-26. Moreover, the present application discusses the creation of variants of the fragments of the disclosed

fragments through the deletion or addition of certain amino acid residues, using techniques well known in the art (page 33, lines 15-21).

In the examples, specific details are provided for making hypersensitive response elicitor fragments and for testing those fragments. Examples 1-5 and 7-8 describe procedures for producing such fragments. In Examples 6 and 11-12, the procedure for testing whether a protein elicits a hypersensitive response is described. Procedures to test proteins for growth enhancement and systemic acquired resistance are set forth in Examples 9-10 and 13-17. These techniques could be readily adapted to make and test additional fragments.

For the reasons stated above, applicants respectfully submit that the rejection of claims 1-9 and 30-38 for lack of written description is improper and should be withdrawn.

The rejection of claims 1-9 and 30-38 under 35 U.S.C. § 112 (2nd para.) for indefiniteness is respectfully traversed in view of the above amendments and the following remarks.

To the extent the rejection is based on a lack of reciting the conditions that will produce the claimed results, applicants respectfully submit that no amendments are necessary. The language of the claims is clear, and it would be unduly limiting to require applicants to restrict the scope of their claims to specific process conditions. Further, one of ordinary skill in the art would be fully able to carry out the claimed method from the disclosure of the present application.

The present application provides ample disclosure of the conditions that are effective to impart disease resistance to plants, enhance plant growth, and/or control insects of plants (pages 37-41 and Examples 16 and 17). As described on pages 37 through 41 of the present application, the methods of the present invention involve the application of protein or polypeptide fragments of hypersensitive response elicitors to plants or plant seeds, or the incorporation of DNA molecules encoding these fragments into transgenic plants. Specific procedures for use in applying the fragments to plants and plant seeds are described on page 40, line 11 through page 41, line 19.

In reference to the USPTO's rejection of claims 30, 33, and 36 based on the alleged lack of clarity regarding the meaning of "applying a fragment of hypersensitive response elicitor protein or polypeptide," the present application makes it clear how this is done. For example, the fragments may be applied to plants (e.g., the leaves, stems, roots, and cuttings of plants) using high or low pressure spraying, injection, and leaf abrasion (page 40, lines 15-18). With respect to seeds and cuttings, the fragments may be applied by low or

Not Entered in claims

high pressure spraying, coating, immersion, or injection (page 40, lines 18-24). Plants propagated from the treated seeds can then be treated again with applications of the fragments of the present invention (page 40, lines 27-31). Examples 16 and 17 provide specific teachings relating to the methods of the present invention, including the conditions for applying the fragments to plants and plant seeds effective to impart disease resistance to plants, to enhance plant growth, and/or control insects of the plants (see also page 41, lines 1-19).

For all these reasons, applicants respectfully submit that the rejection of claims 1-9 and 30-38 for indefiniteness is improper and should be withdrawn.

The rejection of claims 1-9 and 36-38 under 35 U.S.C. § 102(a) as being anticipated by WO 98/37752 to Zitter et al. ("Zitter '752") is respectfully traversed.

Zitter '752 describes a method of insect control for plants by applying a hypersensitive response elicitor polypeptide or protein to the plants. There is no suggestion in Zitter '752 that hypersensitive response elicitor fragments, which themselves do not elicit a hypersensitive response, are useful in controlling insects. Thus, applicants respectfully submit that the 35 U.S.C. § 102(a) rejection based on Zitter '752 is improper and should be withdrawn.

The rejection of claims 1-9 and 30-33 under 35 U.S.C. § 102(a) as being anticipated by WO 96/39802 to Wei et al. ("Wei '802") is respectfully traversed.

Wei '802 teaches a method of imparting pathogen resistance to plants by applying a hypersensitive response elicitor polypeptide or protein to the plants. Wei '802 does not disclose or suggest that hypersensitive response elicitor fragments, which themselves do not elicit a hypersensitive response, are useful in imparting pathogen resistance to plants, enhancing plant growth, or controlling insects of plants. Therefore, applicants respectfully submit that the 35 U.S.C. § 102(a) rejection based on Wei '802 is improper and should be withdrawn.

The rejection of claims 1-3, 8, and 30-32 under 35 U.S.C. § 102(e) as being anticipated by U.S. Patent No. 5,859,324 to Wei et al. ("Wei '324") is respectfully traversed.

Wei '324 is a divisional patent application of U.S. Patent Application Serial No. 08/475,775 to Wei et al., filed June 7, 1995, now abandoned, which corresponds to the international application published as Wei '802 (described above). Thus, Wei '802 and Wei '324 have identical disclosures. Therefore, as with Wei '802, Wei '324 does not disclose or suggest that fragments of a hypersensitive response elicitor protein or polypeptide, which

fragments do not themselves elicit a hypersensitive response, are useful in imparting pathogen resistance to plants, enhancing plant growth, or controlling insects of plants. For these reasons, applicants respectfully submit that the 35 U.S.C. § 102(e) rejection based on Wei '324 is inappropriate and should be withdrawn.

The rejection of claims 1-9 and 30-38 under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 and 26-34 of co-pending U.S. Patent Application Serial No. 09/086,118 ("Patent App. '118)" is respectfully traversed.

Patent App. '118 is directed to hypersensitive response eliciting fragments that elicit a hypersensitive response and the uses of these fragments. However, in contrast to the claims of Patent App. '118, the claims of the present invention are directed to the use of fragments of a hypersensitive response elicitor to impart disease resistance to plants, enhance plant growth, and/or control insects of plants, where the fragments do not themselves elicit a hypersensitive response. Thus, applicants respectfully submit that the double patenting rejection based on the claims of Patent App. '118 is improper and should be withdrawn.

The rejection of claims 36-38 under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 22-27 of U.S. Patent No. 5,977,060 to Zitter et al. ("Zitter '060") is respectfully traversed.

Claims 1 and 22-27 of Zitter '060 are directed to a method of insect control for plants using a hypersensitive response elicitor polypeptide or protein. Since the claims of Zitter '060 are not directed to the use of fragments of hypersensitive response elicitors, which fragments themselves do not elicit a hypersensitive response, in controlling insects, applicants respectfully submit that the double patenting rejection based on Zitter '060 is inappropriate and should be withdrawn.

The rejection of claims 33-35 under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 2, and 19-25 of U.S. Patent No. 6,277,814 to Qiu et al. ("Qiu '814") is respectfully traversed.

The claims of Qiu '814 are directed to a method of enhancing plant growth using a hypersensitive response elicitor polypeptide or protein. The claims of Qiu '814 are not directed to the use of hypersensitive response elicitor fragments, which themselves do not elicit a hypersensitive response, to enhance plant growth. Therefore, the double patenting rejection based on Qiu '814 is improper and should be withdrawn.

The rejection of claims 30-32 under the judicially-created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 2, and 19-23 of U.S. Patent No. 6,235,974 to Qiu et al. ("Qiu '974") is respectfully traversed.

The claims of Qiu '974 are directed to a method of imparting pathogen resistance to plants using hypersensitive response elicitor polypeptides or proteins. However, since the claims of Qiu '974 are not directed to the use of fragments of a hypersensitive response elicitor, which fragments do not themselves achieve a hypersensitive response, in imparting pathogen resistance to plants, the double patenting rejection based on Qiu '974 is inappropriate and should be withdrawn.

In view of all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: May 6, 2002

Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

C rtificat of Mailing - 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office P.O. BOX 2327 Arlington, VA 22202, on the date below.
Date 5/6/2002 Jo Ann Whalen

Appendix A

Version With Markings to Show Changes Made

In reference to the amendments made herein to the specification and to claims 1, 2, 4-7, 9, 30, 33, and 36, additions appear as underlined text, while deletions appear as bracketed text, as indicated below:

In the Specification:

Please replace the paragraph beginning on page 5, line 5, and ending on page 5, line 14, with the following replacement paragraph:

Figure 2 shows a list of synthesized oligonucleotide primers for construction of truncated harpin proteins. N represents the N-terminus (5' region), and C represents the C-terminus (3' region). The primers correspond to the indicated sequence identification numbers for the present application: N1 ([SEQ. ID. No.] SEQ ID NO: 1), N76 ([SEQ. ID. No.] SEQ ID NO: 2), N99 ([SEQ. ID. No.] SEQ ID NO: 3), N105 ([SEQ. ID. No.] SEQ ID NO: 4), N110 ([SEQ. ID. No.] SEQ ID NO: 5), N137 ([SEQ. ID. No.] SEQ ID NO: 6), N150 ([SEQ. ID. No.] SEQ ID NO: 7), N169 ([SEQ. ID. No.] SEQ ID NO: 8), N210 ([SEQ. ID. No.] SEQ ID NO: 9), N267 ([SEQ. ID. No.] SEQ ID NO: 10), N343 ([SEQ. ID. No.] SEQ ID NO: 11), C75 ([SEQ. ID. No.] SEQ ID NO: 12), C104 ([SEQ. ID. No.] SEQ ID NO: 13), C168 ([SEQ. ID. No.] SEQ ID NO: 14), C180 ([SEQ. ID. No.] SEQ ID NO: 15), C204 ([SEQ. ID. No.] SEQ ID NO: 16), C209 ([SEQ. ID. No.] SEQ ID NO: 17), C266 ([SEQ. ID. No.] SEQ ID NO: 18), C342 ([SEQ. ID. No.] SEQ ID NO: 19), and C403 ([SEQ. ID. No.] SEQ ID NO: 20).

Please replace the paragraph beginning on page 6, line 5, and ending on page 8, line 22, with the following replacement paragraph:

The hypersensitive response elicitor polypeptide or protein from *Erwinia chrysanthemi* has an amino acid sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 21 as follows:

```
Met Gln Ile Thr Ile Lys Ala His Ile Gly Gly Asp Leu Gly Val Ser
1               5                  10                  15

Gly Leu Gly Ala Gln Gly Leu Lys Gly Leu Asn Ser Ala Ala Ser Ser
            20                  25                  30
```

Appendix A

Version With Markings to Show Changes Made


```
Leu Gly Ser Ser Val Asp Lys Leu Ser Ser Thr Ile Asp Lys Leu Thr
        35                  40                  45

Ser Ala Leu Thr Ser Met Met Phe Gly Gly Ala Leu Ala Gln Gly Leu
    50                  55                  60

Gly Ala Ser Ser Lys Gly Leu Gly Met Ser Asn Gln Leu Gly Gln Ser
65                  70                  75                  80

Phe Gly Asn Gly Ala Gln Gly Ala Ser Asn Leu Leu Ser Val Pro Lys
                85                  90                  95

Ser Gly Gly Asp Ala Leu Ser Lys Met Phe Asp Lys Ala Leu Asp Asp
            100                 105                 110

Leu Leu Gly His Asp Thr Val Thr Lys Leu Thr Asn Gln Ser Asn Gln
        115                 120                 125

Leu Ala Asn Ser Met Leu Asn Ala Ser Gln Met Thr Gln Gly Asn Met
    130                 135                 140

Asn Ala Phe Gly Ser Gly Val Asn Asn Ala Leu Ser Ser Ile Leu Gly
145                 150                 155                 160

Asn Gly Leu Gly Gln Ser Met Ser Gly Phe Ser Gln Pro Ser Leu Gly
                165                 170                 175

Ala Gly Gly Leu Gln Gly Leu Ser Gly Ala Gly Ala Phe Asn Gln Leu
            180                 185                 190

Gly Asn Ala Ile Gly Met Gly Val Gly Gln Asn Ala Ala Leu Ser Ala
        195                 200                 205

Leu Ser Asn Val Ser Thr His Val Asp Gly Asn Asn Arg His Phe Val
    210                 215                 220

Asp Lys Glu Asp Arg Gly Met Ala Lys Glu Ile Gly Gln Phe Met Asp
225                 230                 235                 240

Gln Tyr Pro Glu Ile Phe Gly Lys Pro Glu Tyr Gln Lys Asp Gly Trp
                245                 250                 255

Ser Ser Pro Lys Thr Asp Asp Lys Ser Trp Ala Lys Ala Leu Ser Lys
            260                 265                 270

Pro Asp Asp Asp Gly Met Thr Gly Ala Ser Met Asp Lys Phe Arg Gln
        275                 280                 285

Ala Met Gly Met Ile Lys Ser Ala Val Ala Gly Asp Thr Gly Asn Thr
    290                 295                 300

Asn Leu Asn Leu Arg Gly Ala Gly Gly Ala Ser Leu Gly Ile Asp Ala
305                 310                 315                 320
```

```
Ala Val Val Gly Asp Lys Ile Ala Asn Met Ser Leu Gly Lys Leu Ala
                325                 330                 335

Asn Ala
```

This hypersensitive response elicitor polypeptide or protein has a molecular weight of 34 kDa, is heat stable, has a glycine content of greater than 16%, and contains substantially no cysteine. The *Erwinia chrysanthemi* hypersensitive response elicitor polypeptide or protein is encoded by a DNA molecule having a nucleotide sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 22 as follows:

```
CGATTTTACC CGGGTGAACG TGCTATGACC GACAGCATCA CGGTATTCGA CACCGTTACG      60

GCGTTTATGG CCGCGATGAA CCGGCATCAG GCGGCGCGCT GGTCGCCGCA ATCCGGCGTC     120

GATCTGGTAT TTCAGTTTGG GGACACCGGG CGTGAACTCA TGATGCAGAT TCAGCCGGGG     180

CAGCAATATC CCGGCATGTT GCGCACGCTG CTCGCTCGTC GTTATCAGCA GGCGGCAGAG     240

TGCGATGGCT GCCATCTGTG CCTGAACGGC AGCGATGTAT TGATCCTCTG GTGGCCGCTG     300

CCGTCGGATC CCGGCAGTTA TCCGCAGGTG ATCGAACGTT TGTTTGAACT GGCGGGAATG     360

ACGTTGCCGT CGCTATCCAT AGCACCGACG GCGCGTCCGC AGACAGGGAA CGGACGCGCC     420

CGATCATTAA GATAAAGGCG GCTTTTTTTA TTGCAAAACG GTAACGGTGA GGAACCGTTT     480

CACCGTCGGC GTCACTCAGT AACAAGTATC CATCATGATG CCTACATCGG GATCGGCGTG     540

GGCATCCGTT GCAGATACTT TTGCGAACAC CTGACATGAA TGAGGAAACG AAATTATGCA     600

AATTACGATC AAAGCGCACA TCGGCGGTGA TTTGGGCGTC TCCGGTCTGG GGCTGGGTGC     660

TCAGGGACTG AAAGGACTGA ATTCCGCGGC TTCATCGCTG GGTTCCAGCG TGGATAAACT     720

GAGCAGCACC ATCGATAAGT TGACCTCCGC GCTGACTTCG ATGATGTTTG GCGGCGCGCT     780

GGCGCAGGGG CTGGGCGCCA GCTCGAAGGG GCTGGGGATG AGCAATCAAC TGGGCCAGTC     840

TTTCGGCAAT GGCGCGCAGG GTGCGAGCAA CCTGCTATCC GTACCGAAAT CCGGCGGCGA     900

TGCGTTGTCA AAAATGTTTG ATAAAGCGCT GGACGATCTG CTGGGTCATG ACACCGTGAC     960

CAAGCTGACT AACCAGAGCA ACCAACTGGC TAATTCAATG CTGAACGCCA GCCAGATGAC    1020

CCAGGGTAAT ATGAATGCGT TCGGCAGCGG TGTGAACAAC GCACTGTCGT CCATTCTCGG    1080

CAACGGTCTC GGCCAGTCGA TGAGTGGCTT CTCTCAGCCT TCTCTGGGGG CAGGCGGCTT    1140

GCAGGGCCTG AGCGGCGCGG GTGCATTCAA CCAGTTGGGT AATGCCATCG GCATGGGCGT    1200
```

Appendix A

Version With Markings to Show Changes Made


```
GGGGCAGAAT GCTGCGCTGA GTGCGTTGAG TAACGTCAGC ACCCACGTAG ACGGTAACAA    1260

CCGCCACTTT GTAGATAAAG AAGATCGCGG CATGGCGAAA GAGATCGGCC AGTTTATGGA    1320

TCAGTATCCG GAAATATTCG GTAAACCGGA ATACCAGAAA GATGGCTGGA GTTCGCCGAA    1380

GACGGACGAC AAATCCTGGG CTAAAGCGCT GAGTAAACCG GATGATGACG GTATGACCGG    1440

CGCCAGCATG GACAAATTCC GTCAGGCGAT GGGTATGATC AAAAGCGCGG TGGCGGGTGA    1500

TACCGGCAAT ACCAACCTGA ACCTGCGTGG CGCGGGCGGT GCATCGCTGG GTATCGATGC    1560

GGCTGTCGTC GGCGATAAAA TAGCCAACAT GTCGCTGGGT AAGCTGGCCA ACGCCTGATA    1620

ATCTGTGCTG GCCTGATAAA GCGGAAACGA AAAAAGAGAC GGGGAAGCCT GTCTCTTTTC    1680

TTATTATGCG GTTTATGCGG TTACCTGGAC CGGTTAATCA TCGTCATCGA TCTGGTACAA    1740

ACGCACATTT TCCCGTTCAT TCGCGTCGTT ACGCGCCACA ATCGCGATGG CATCTTCCTC    1800

GTCGCTCAGA TTGCGCGGCT GATGGGGAAC GCCGGGTGGA ATATAGAGAA ACTCGCCGGC    1860

CAGATGGAGA CACGTCTGCG ATAAATCTGT GCCGTAACGT GTTTCTATCC GCCCCTTTAG    1920

CAGATAGATT GCGGTTTCGT AATCAACATG GTAATGCGGT TCCGCCTGTG CGCCGGCCGG    1980

GATCACCACA ATATTCATAG AAAGCTGTCT TGCACCTACC GTATCGCGGG AGATACCGAC    2040

AAAATAGGGC AGTTTTTGCG TGGTATCCGT GGGGTGTTCC GGCCTGACAA TCTTGAGTTG    2100

GTTCGTCATC ATCTTTCTCC ATCTGGGCGA CCTGATCGGT T                        2141
```

Please replace the paragraph beginning on page 8, line 25, and ending on page 11, line 8, with the following replacement paragraph:

The hypersensitive response elicitor polypeptide or protein derived from *Erwinia amylovora* has an amino acid sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 23 as follows:

```
Met Ser Leu Asn Thr Ser Gly Leu Gly Ala Ser Thr Met Gln Ile Ser
1               5                  10                  15

Ile Gly Gly Ala Gly Gly Asn Asn Gly Leu Leu Gly Thr Ser Arg Gln
            20                  25                  30

Asn Ala Gly Leu Gly Gly Asn Ser Ala Leu Gly Leu Gly Gly Gly Asn
        35                  40                  45
```

Appendix A

Version With Markings to Show Changes Made


```
Gln Asn Asp Thr Val Asn Gln Leu Ala Gly Leu Leu Thr Gly Met Met
    50                  55                  60

Met Met Met Ser Met Met Gly Gly Gly Gly Leu Met Gly Gly Gly Leu
65                  70                  75                  80

Gly Gly Gly Leu Gly Asn Gly Leu Gly Gly Ser Gly Gly Leu Gly Glu
                85                  90                  95

Gly Leu Ser Asn Ala Leu Asn Asp Met Leu Gly Gly Ser Leu Asn Thr
            100                 105                 110

Leu Gly Ser Lys Gly Gly Asn Asn Thr Thr Ser Thr Thr Asn Ser Pro
        115                 120                 125

Leu Asp Gln Ala Leu Gly Ile Asn Ser Thr Ser Gln Asn Asp Asp Ser
    130                 135                 140

Thr Ser Gly Thr Asp Ser Thr Ser Asp Ser Ser Asp Pro Met Gln Gln
145                 150                 155                 160

Leu Leu Lys Met Phe Ser Glu Ile Met Gln Ser Leu Phe Gly Asp Gly
                165                 170                 175

Gln Asp Gly Thr Gln Gly Ser Ser Ser Gly Gly Lys Gln Pro Thr Glu
            180                 185                 190

Gly Glu Gln Asn Ala Tyr Lys Lys Gly Val Thr Asp Ala Leu Ser Gly
        195                 200                 205

Leu Met Gly Asn Gly Leu Ser Gln Leu Leu Gly Asn Gly Gly Leu Gly
    210                 215                 220

Gly Gly Gln Gly Gly Asn Ala Gly Thr Gly Leu Asp Gly Ser Ser Leu
225                 230                 235                 240

Gly Gly Lys Gly Leu Gln Asn Leu Ser Gly Pro Val Asp Tyr Gln Gln
                245                 250                 255

Leu Gly Asn Ala Val Gly Thr Gly Ile Gly Met Lys Ala Gly Ile Gln
            260                 265                 270

Ala Leu Asn Asp Ile Gly Thr His Arg His Ser Ser Thr Arg Ser Phe
        275                 280                 285

Val Asn Lys Gly Asp Arg Ala Met Ala Lys Glu Ile Gly Gln Phe Met
    290                 295                 300

Asp Gln Tyr Pro Glu Val Phe Gly Lys Pro Gln Tyr Gln Lys Gly Pro
305                 310                 315                 320

Gly Gln Glu Val Lys Thr Asp Asp Lys Ser Trp Ala Lys Ala Leu Ser
                325                 330                 335
```

Appendix A

Version With Markings to Show Changes Made


```
Lys Pro Asp Asp Asp Gly Met Thr Pro Ala Ser Met Glu Gln Phe Asn
            340                 345                 350

Lys Ala Lys Gly Met Ile Lys Arg Pro Met Ala Gly Asp Thr Gly Asn
        355                 360                 365

Gly Asn Leu Gln Ala Arg Gly Ala Gly Gly Ser Ser Leu Gly Ile Asp
    370                 375                 380

Ala Met Met Ala Gly Asp Ala Ile Asn Asn Met Ala Leu Gly Lys Leu
385                 390                 395                 400

Gly Ala Ala
```

This hypersensitive response elicitor polypeptide or protein has a molecular weight of about 39 kDa, has a pI of approximately 4.3, and is heat stable at 100°C for at least 10 minutes. This hypersensitive response elicitor polypeptide or protein has substantially no cysteine. The hypersensitive response elicitor polypeptide or protein derived from *Erwinia amylovora* is more fully described in Wei, Z.-M., R. J. Laby, C. H. Zumoff, D. W. Bauer, S.-Y. He, A. Collmer, and S. V. Beer, "Harpin, Elicitor of the Hypersensitive Response Produced by the Plant Pathogen *Erwinia amylovora*," Science 257:85-88 (1992), which is hereby incorporated by reference. The DNA molecule encoding this polypeptide or protein has a nucleotide sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 24 as follows:

```
AAGCTTCGGC ATGGCACGTT TGACCGTTGG GTCGGCAGGG TACGTTTGAA TTATTCATAA      60

GAGGAATACG TTATGAGTCT GAATACAAGT GGGCTGGGAG CGTCAACGAT GCAAATTTCT     120

ATCGGCGGTG CGGGCGGAAA TAACGGGTTG CTGGGTACCA GTCGCCAGAA TGCTGGGTTG     180

GGTGGCAATT CTGCACTGGG GCTGGGCGGC GGTAATCAAA ATGATACCGT CAATCAGCTG     240

GCTGGCTTAC TCACCGGCAT GATGATGATG ATGAGCATGA TGGGCGGTGG TGGGCTGATG     300

GGCGGTGGCT TAGGCGGTGG CTTAGGTAAT GGCTTGGGTG GCTCAGGTGG CCTGGGCGAA     360

GGACTGTCGA ACGCGCTGAA CGATATGTTA GGCGGTTCGC TGAACACGCT GGGCTCGAAA     420

GGCGGCAACA ATACCACTTC AACAACAAAT TCCCCGCTGG ACCAGGCGCT GGGTATTAAC     480

TCAACGTCCC AAAACGACGA TTCCACCTCC GGCACAGATT CCACCTCAGA CTCCAGCGAC     540

CCGATGCAGC AGCTGCTGAA GATGTTCAGC GAGATAATGC AAAGCCTGTT TGGTGATGGG     600

CAAGATGGCA CCCAGGGCAG TTCCTCTGGG GGCAAGCAGC CGACCGAAGG CGAGCAGAAC     660

GCCTATAAAA AAGGAGTCAC TGATGCGCTG TCGGGCCTGA TGGGTAATGG TCTGAGCCAG     720

CTCCTTGGCA ACGGGGGACT GGGAGGTGGT CAGGGCGGTA ATGCTGGCAC GGGTCTTGAC     780
```

```
GGTTCGTCGC TGGGCGGCAA AGGGCTGCAA AACCTGAGCG GGCCGGTGGA CTACCAGCAG     840

TTAGGTAACG CCGTGGGTAC CGGTATCGGT ATGAAAGCGG GCATTCAGGC GCTGAATGAT     900

ATCGGTACGC ACAGGCACAG TTCAACCCGT TCTTTCGTCA ATAAAGGCGA TCGGGCGATG     960

GCGAAGGAAA TCGGTCAGTT CATGGACCAG TATCCTGAGG TGTTTGGCAA GCCGCAGTAC    1020

CAGAAAGGCC CGGGTCAGGA GGTGAAAACC GATGACAAAT CATGGGCAAA AGCACTGAGC    1080

AAGCCAGATG ACGACGGAAT GACACCAGCC AGTATGGAGC AGTTCAACAA AGCCAAGGGC    1140

ATGATCAAAA GGCCCATGGC GGGTGATACC GGCAACGGCA ACCTGCAGGC ACGCGGTGCC    1200

GGTGGTTCTT CGCTGGGTAT TGATGCCATG ATGGCCGGTG ATGCCATTAA CAATATGGCA    1260

CTTGGCAAGC TGGGCGCGGC TTAAGCTT                                       1288
```

Please replace the paragraph beginning on page 11, line 11, and ending on page 13, line 47, with the following replacement paragraph:

Another potentially suitable hypersensitive response elicitor from *Erwinia amylovora* is disclosed in U.S. Patent Application Serial No. 09/120,927, which is hereby incorporated by reference. The protein is encoded by a DNA molecule having a nucleic acid sequence of [SEQ. ID. No.] SEQ ID NO: 25 as follows:

```
ATGTCAATTC TTACGCTTAA CAACAATACC TCGTCCTCGC CGGGTCTGTT CCAGTCCGGG      60

GGGGACAACG GGCTTGGTGG TCATAATGCA AATTCTGCGT TGGGGCAACA ACCCATCGAT     120

CGGCAAACCA TTGAGCAAAT GGCTCAATTA TTGGCGGAAC TGTTAAAGTC ACTGCTATCG     180

CCACAATCAG GTAATGCGGC AACCGGAGCC GGTGGCAATG ACCAGACTAC AGGAGTTGGT     240

AACGCTGGCG GCCTGAACGG ACGAAAAGGC ACAGCAGGAA CCACTCCGCA GTCTGACAGT     300

CAGAACATGC TGAGTGAGAT GGGCAACAAC GGGCTGGATC AGGCCATCAC GCCCGATGGC     360

CAGGGCGGCG GGCAGATCGG CGATAATCCT TTACTGAAAG CCATGCTGAA GCTTATTGCA     420

CGCATGATGG ACGGCCAAAG CGATCAGTTT GGCCAACCTG GTACGGGCAA CAACAGTGCC     480

TCTTCCGGTA CTTCTTCATC TGGCGGTTCC CCTTTTAACG ATCTATCAGG GGGGAAGGCC     540

CCTTCCGGCA ACTCCCCTTC CGGCAACTAC TCTCCCGTCA GTACCTTCTC ACCCCCATCC     600

ACGCCAACGT CCCCTACCTC ACCGCTTGAT TTCCCTTCTT CTCCCACCAA AGCAGCCGGG     660

GGCAGCACGC CGGTAACCGA TCATCCTGAC CCTGTTGGTA GCGCGGGCAT CGGGGCCGGA     720

AATTCGGTGG CCTTCACCAG CGCCGGCGCT AATCAGACGG TGCTGCATGA CACCATTACC     780
```

```
GTGAAAGCGG GTCAGGTGTT TGATGGCAAA GGACAAACCT TCACCGCCGG TTCAGAATTA     840

GGCGATGGCG GCCAGTCTGA AAACCAGAAA CCGCTGTTTA TACTGGAAGA CGGTGCCAGC     900

CTGAAAAACG TCACCATGGG CGACGACGGG GCGGATGGTA TTCATCTTTA CGGTGATGCC     960

AAAATAGACA ATCTGCACGT CACCAACGTG GGTGAGGACG CGATTACCGT TAAGCCAAAC    1020

AGCGCGGGCA AAAAATCCCA CGTTGAAATC ACTAACAGTT CCTTCGAGCA CGCCTCTGAC    1080

AAGATCCTGC AGCTGAATGC CGATACTAAC CTGAGCGTTG ACAACGTGAA GGCCAAAGAC    1140

TTTGGTACTT TTGTACGCAC TAACGGCGGT CAACAGGGTA ACTGGGATCT GAATCTGAGC    1200

CATATCAGCG CAGAAGACGG TAAGTTCTCG TTCGTTAAAA GCGATAGCGA GGGGCTAAAC    1260

GTCAATACCA GTGATATCTC ACTGGGTGAT GTTGAAAACC ACTACAAAGT GCCGATGTCC    1320

GCCAACCTGA AGGTGGCTGA ATGA                                           1344
```

See GenBank Accession No. U94513. The isolated DNA molecule of the present invention encodes a hypersensitive response elicitor protein or polypeptide having an amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 26 as follows:

```
Met Ser Ile Leu Thr Leu Asn Asn Asn Thr Ser Ser Ser Pro Gly Leu
1               5                  10                  15

Phe Gln Ser Gly Gly Asp Asn Gly Leu Gly Gly His Asn Ala Asn Ser
            20                  25                  30

Ala Leu Gly Gln Gln Pro Ile Asp Arg Gln Thr Ile Glu Gln Met Ala
        35                  40                  45

Gln Leu Leu Ala Glu Leu Leu Lys Ser Leu Leu Ser Pro Gln Ser Gly
    50                  55                  60

Asn Ala Ala Thr Gly Ala Gly Gly Asn Asp Gln Thr Thr Gly Val Gly
65                  70                  75                  80

Asn Ala Gly Gly Leu Asn Gly Arg Lys Gly Thr Ala Gly Thr Thr Pro
                85                  90                  95

Gln Ser Asp Ser Gln Asn Met Leu Ser Glu Met Gly Asn Asn Gly Leu
            100                 105                 110

Asp Gln Ala Ile Thr Pro Asp Gly Gln Gly Gly Gly Gln Ile Gly Asp
        115                 120                 125

Asn Pro Leu Leu Lys Ala Met Leu Lys Leu Ile Ala Arg Met Met Asp
    130                 135                 140

Gly Gln Ser Asp Gln Phe Gly Gln Pro Gly Thr Gly Asn Asn Ser Ala
145                 150                 155                 160
```

Appendix A

Version With Markings to Show Changes Made


```
Ser Ser Gly Thr Ser Ser Ser Gly Gly Ser Pro Phe Asn Asp Leu Ser
                165                 170                 175

Gly Gly Lys Ala Pro Ser Gly Asn Ser Pro Ser Gly Asn Tyr Ser Pro
            180                 185                 190

Val Ser Thr Phe Ser Pro Pro Ser Thr Pro Thr Ser Pro Thr Ser Pro
        195                 200                 205

Leu Asp Phe Pro Ser Ser Pro Thr Lys Ala Ala Gly Gly Ser Thr Pro
    210                 215                 220

Val Thr Asp His Pro Asp Pro Val Gly Ser Ala Gly Ile Gly Ala Gly
225                 230                 235                 240

Asn Ser Val Ala Phe Thr Ser Ala Gly Ala Asn Gln Thr Val Leu His
                245                 250                 255

Asp Thr Ile Thr Val Lys Ala Gly Gln Val Phe Asp Gly Lys Gly Gln
            260                 265                 270

Thr Phe Thr Ala Gly Ser Glu Leu Gly Asp Gly Gly Gln Ser Glu Asn
        275                 280                 285

Gln Lys Pro Leu Phe Ile Leu Glu Asp Gly Ala Ser Leu Lys Asn Val
    290                 295                 300

Thr Met Gly Asp Asp Gly Ala Asp Gly Ile His Leu Tyr Gly Asp Ala
305                 310                 315                 320

Lys Ile Asp Asn Leu His Val Thr Asn Val Gly Glu Asp Ala Ile Thr
                325                 330                 335

Val Lys Pro Asn Ser Ala Gly Lys Lys Ser His Val Glu Ile Thr Asn
            340                 345                 350

Ser Ser Phe Glu His Ala Ser Asp Lys Ile Leu Gln Leu Asn Ala Asp
        355                 360                 365

Thr Asn Leu Ser Val Asp Asn Val Lys Ala Lys Asp Phe Gly Thr Phe
    370                 375                 380

Val Arg Thr Asn Gly Gly Gln Gln Gly Asn Trp Asp Leu Asn Leu Ser
385                 390                 395                 400

His Ile Ser Ala Glu Asp Gly Lys Phe Ser Phe Val Lys Ser Asp Ser
                405                 410                 415

Glu Gly Leu Asn Val Asn Thr Ser Asp Ile Ser Leu Gly Asp Val Glu
            420                 425                 430

Asn His Tyr Lys Val Pro Met Ser Ala Asn Leu Lys Val Ala Glu
        435                 440                 445
```

This protein or polypeptide is acidic, rich in glycine and serine, and lacks cysteine. It is also heat stable, protease sensitive, and suppressed by inhibitors of plant metabolism. The protein or polypeptide of the present invention has a predicted molecular size of ca. 4.5 kDa.

Please replace the paragraph beginning on page 13, line 48, and ending on page 22, line 24, with the following replacement paragraph:

Another potentially suitable hypersensitive response elicitor from *Erwinia amylovora* is disclosed in U.S. Patent Application Serial No. 09/120,663 which is hereby incorporated by reference. The protein is encoded by a DNA molecule having a nucleic acid sequence of [SEQ. ID. No.] SEQ ID NO: 27 as follows:

```
ATGGAATTAA AATCACTGGG AACTGAACAC AAGGCGGCAG TACACACAGC GGCGCACAAC      60
CCTGTGGGGC ATGGTGTTGC CTTACAGCAG GGCAGCAGCA GCAGCAGCCC GCAAAATGCC     120
GCTGCATCAT TGGCGGCAGA AGGCAAAAAT CGTGGGAAAA TGCCGAGAAT TCACCAGCCA     180
TCTACTGCGG CTGATGGTAT CAGCGCTGCT CACCAGCAAA AGAAATCCTT CAGTCTCAGG     240
GGCTGTTTGG GGACGAAAAA ATTTTCCAGA TCGGCACCGC AGGGCCAGCC AGGTACCACC     300
CACAGCAAAG GGGCAACATT GCGCGATCTG CTGGCGCGGG ACGACGGCGA AACGCAGCAT     360
GAGGCGGCCG CGCCAGATGC GGCGCGTTTG ACCCGTTCGG GCGGCGTCAA ACGCCGCAAT     420
ATGGACGACA TGGCCGGGCG GCCAATGGTG AAAGGTGGCA GCGGCGAAGA TAAGGTACCA     480
ACGCAGCAAA AACGGCATCA GCTGAACAAT TTTGGCCAGA TGCGCCAAAC GATGTTGAGC     540
AAAATGGCTC ACCCGGCTTC AGCCAACGCC GGCGATCGCC TGCAGCATTC ACCGCCGCAC     600
ATCCCGGGTA GCCACCACGA AATCAAGGAA GAACCGGTTG GCTCCACCAG CAAGGCAACA     660
ACGGCCCACG CAGACAGAGT GGAAATCGCT CAGGAAGATG ACGACAGCGA ATTCCAGCAA     720
CTGCATCAAC AGCGGCTGGC GCGCGAACGG GAAAATCCAC CGCAGCCGCC CAAACTCGGC     780
GTTGCCACAC CGATTAGCGC CAGGTTTCAG CCCAAACTGA CTGCGGTTGC GGAAAGCGTC     840
CTTGAGGGGA CAGATACCAC GCAGTCACCC CTTAAGCCGC AATCAATGCT GAAAGGAAGT     900
GGAGCCGGGG TAACGCCGCT GGCGGTAACG CTGGATAAAG GCAAGTTGCA GCTGGCACCG     960
GATAATCCAC CCGCGCTCAA TACGTTGTTG AAGCAGACAT TGGGTAAAGA CACCCAGCAC    1020
TATCTGGCGC ACCATGCCAG CAGCGACGGT AGCCAGCATC TGCTGCTGGA CAACAAAGGC    1080
CACCTGTTTG ATATCAAAAG CACCGCCACC AGCTATAGCG TGCTGCACAA CAGCCACCCC    1140
GGTGAGATAA AGGGCAAGCT GGCGCAGGCG GGTACTGGCT CCGTCAGCGT AGACGGTAAA    1200
```

Appendix A

Version With Markings to Show Changes Made

AGCGGCAAGA TCTCGCTGGG GAGCGGTACG CAAAGTCACA ACAAAACAAT GCTAAGCCAA 1260

CCGGGGGAAG CGCACCGTTC CTTATTAACC GGCATTTGGC AGCATCCTGC TGGCGCAGCG 1320

CGGCCGCAGG GCGAGTCAAT CCGCCTGCAT GACGACAAAA TTCATATCCT GCATCCGGAG 1380

CTGGGCGTAT GGCAATCTGC GGATAAAGAT ACCCACAGCC AGCTGTCTCG CCAGGCAGAC 1440

GGTAAGCTCT ATGCGCTGAA AGACAACCGT ACCCTGCAAA ACCTCTCCGA TAATAAATCC 1500

TCAGAAAAGC TGGTCGATAA AATCAAATCG TATTCCGTTG ATCAGCGGGG GCAGGTGGCG 1560

ATCCTGACGG ATACTCCCGG CCGCCATAAG ATGAGTATTA TGCCCTCGCT GGATGCTTCC 1620

CCGGAGAGCC ATATTTCCCT CAGCCTGCAT TTTGCCGATG CCCACCAGGG GTTATTGCAC 1680

GGGAAGTCGG AGCTTGAGGC ACAATCTGTC GCGATCAGCC ATGGGCGACT GGTTGTGGCC 1740

GATAGCGAAG GCAAGCTGTT TAGCGCCGCC ATTCCGAAGC AAGGGGATGG AAACGAACTG 1800

AAAATGAAAG CCATGCCTCA GCATGCGCTC GATGAACATT TTGGTCATGA CCACCAGATT 1860

TCTGGATTTT TCCATGACGA CCACGGCCAG CTTAATGCGC TGGTGAAAAA TAACTTCAGG 1920

CAGCAGCATG CCTGCCCGTT GGGTAACGAT CATCAGTTTC ACCCCGGCTG GAACCTGACT 1980

GATGCGCTGG TTATCGACAA TCAGCTGGGG CTGCATCATA CCAATCCTGA ACCGCATGAG 2040

ATTCTTGATA TGGGGCATTT AGGCAGCCTG GCGTTACAGG AGGGCAAGCT TCACTATTTT 2100

GACCAGCTGA CCAAAGGGTG GACTGGCGCG GAGTCAGATT GTAAGCAGCT GAAAAAAGGC 2160

CTGGATGGAG CAGCTTATCT ACTGAAAGAC GGTGAAGTGA AACGCCTGAA TATTAATCAG 2220

AGCACCTCCT CTATCAAGCA CGGAACGGAA AACGTTTTTT CGCTGCCGCA TGTGCGCAAT 2280

AAACCGGAGC CGGGAGATGC CCTGCAAGGG CTGAATAAAG ACGATAAGGC CCAGGCCATG 2340

GCGGTGATTG GGGTAAATAA ATACCTGGCG CTGACGGAAA AAGGGGACAT TCGCTCCTTC 2400

CAGATAAAAC CCGGCACCCA GCAGTTGGAG CGGCCGGCAC AAACTCTCAG CCGCGAAGGT 2460

ATCAGCGGCG AACTGAAAGA CATTCATGTC GACCACAAGC AGAACCTGTA TGCCTTGACC 2520

CACGAGGGAG AGGTGTTTCA TCAGCCGCGT GAAGCCTGGC AGAATGGTGC CGAAAGCAGC 2580

AGCTGGCACA AACTGGCGTT GCCACAGAGT GAAAGTAAGC TAAAAAGTCT GGACATGAGC 2640

CATGAGCACA AACCGATTGC CACCTTTGAA GACGGTAGCC AGCATCAGCT GAAGGCTGGC 2700

GGCTGGCACG CCTATGCGGC ACCTGAACGC GGGCCGCTGG CGGTGGGTAC CAGCGGTTCA 2760

CAAACCGTCT TTAACCGACT AATGCAGGGG GTGAAAGGCA AGGTGATCCC AGGCAGCGGG 2820

TTGACGGTTA AGCTCTCGGC TCAGACGGGG GGAATGACCG GCGCCGAAGG GCGCAAGGTC 2880

AGCAGTAAAT TTTCCGAAAG GATCCGCGCC TATGCGTTCA ACCCAACAAT GTCCACGCCG 2940

CGACCGATTA AAAATGCTGC TTATGCCACA CAGCACGGCT GGCAGGGGCG TGAGGGGTTG 3000

AAGCCGTTGT ACGAGATGCA GGGAGCGCTG ATTAAACAAC TGGATGCGCA TAACGTTCGT 3060

CATAACGCGC CACAGCCAGA TTTGCAGAGC AAACTGGAAA CTCTGGATTT AGGCGAACAT 3120

GGCGCAGAAT TGCTTAACGA CATGAAGCGC TTCCGCGACG AACTGGAGCA GAGTGCAACC 3180

CGTTCGGTGA CCGTTTTAGG TCAACATCAG GGAGTGCTAA AAAGCAACGG TGAAATCAAT 3240

AGCGAATTTA AGCCATCGCC CGGCAAGGCG TTGGTCCAGA GCTTTAACGT CAATCGCTCT 3300

GGTCAGGATC TAAGCAAGTC ACTGCAACAG GCAGTACATG CCACGCCGCC ATCCGCAGAG 3360

AGTAAACTGC AATCCATGCT GGGGCACTTT GTCAGTGCCG GGGTGGATAT GAGTCATCAG 3420

AAGGGCGAGA TCCCGCTGGG CCGCCAGCGC GATCCGAATG ATAAAACCGC ACTGACCAAA 3480

TCGCGTTTAA TTTTAGATAC CGTGACCATC GGTGAACTGC ATGAACTGGC CGATAAGGCG 3540

AAACTGGTAT CTGACCATAA ACCCGATGCC GATCAGATAA AACAGCTGCG CCAGCAGTTC 3600

GATACGCTGC GTGAAAAGCG GTATGAGAGC AATCCGGTGA AGCATTACAC CGATATGGGC 3660

TTCACCCATA ATAAGGCGCT GGAAGCAAAC TATGATGCGG TCAAAGCCTT TATCAATGCC 3720

TTTAAGAAAG AGCACCACGG CGTCAATCTG ACCACGCGTA CCGTACTGGA ATCACAGGGC 3780

AGTGCGGAGC TGGCGAAGAA GCTCAAGAAT ACGCTGTTGT CCCTGGACAG TGGTGAAAGT 3840

ATGAGCTTCA GCCGGTCATA TGGCGGGGGC GTCAGCACTG TCTTTGTGCC TACCCTTAGC 3900

AAGAAGGTGC CAGTTCCGGT GATCCCCGGA GCCGGCATCA CGCTGGATCG CGCCTATAAC 3960

CTGAGCTTCA GTCGTACCAG CGGCGGATTG AACGTCAGTT TTGGCCGCGA CGGCGGGGTG 4020

AGTGGTAACA TCATGGTCGC TACCGGCCAT GATGTGATGC CCTATATGAC CGGTAAGAAA 4080

ACCAGTGCAG GTAACGCCAG TGACTGGTTG AGCGCAAAAC ATAAAATCAG CCCGGACTTG 4140

CGTATCGGCG CTGCTGTGAG TGGCACCCTG CAAGGAACGC TACAAAACAG CCTGAAGTTT 4200

AAGCTGACAG AGGATGAGCT GCCTGGCTTT ATCCATGGCT TGACGCATGG CACGTTGACC 4260

CCGGCAGAAC TGTTGCAAAA GGGGATCGAA CATCAGATGA AGCAGGGCAG CAAACTGACG 4320

TTTAGCGTCG ATACCTCGGC AAATCTGGAT CTGCGTGCCG GTATCAATCT GAACGAAGAC 4380

GGCAGTAAAC CAAATGGTGT CACTGCCCGT GTTTCTGCCG GGCTAAGTGC ATCGGCAAAC 4440

CTGGCCGCCG GCTCGCGTGA ACGCAGCACC ACCTCTGGCC AGTTTGGCAG CACGACTTCG 4500

GCCAGCAATA ACCGCCCAAC CTTCCTCAAC GGGGTCGGCG CGGGTGCTAA CCTGACGGCT 4560

GCTTTAGGGG TTGCCCATTC ATCTACGCAT GAAGGGAAAC CGGTCGGGAT CTTCCCGGCA 4620

TTTACCTCGA CCAATGTTTC GGCAGCGCTG GCGCTGGATA ACCGTACCTC ACAGAGTATC 4680

AGCCTGGAAT TGAAGCGCGC GGAGCCGGTG ACCAGCAACG ATATCAGCGA GTTGACCTCC 4740

ACGCTGGGAA AACACTTTAA GGATAGCGCC ACAACGAAGA TGCTTGCCGC TCTCAAAGAG 4800

TTAGATGACG CTAAGCCCGC TGAACAACTG CATATTTTAC AGCAGCATTT CAGTGCAAAA 4860

GATGTCGTCG GTGATGAACG CTACGAGGCG GTGCGCAACC TGAAAAAACT GGTGATACGT 4920

```
CAACAGGCTG CGGACAGCCA CAGCATGGAA TTAGGATCTG CCAGTCACAG CACGACCTAC    4980

AATAATCTGT CGAGAATAAA TAATGACGGC ATTGTCGAGC TGCTACACAA ACATTTCGAT    5040

GCGGCATTAC CAGCAAGCAG TGCCAAACGT CTTGGTGAAA TGATGAATAA CGATCCGGCA    5100

CTGAAAGATA TTATTAAGCA GCTGCAAAGT ACGCCGTTCA GCAGCGCCAG CGTGTCGATG    5160

GAGCTGAAAG ATGGTCTGCG TGAGCAGACG GAAAAAGCAA TACTGGACGG TAAGGTCGGT    5220

CGTGAAGAAG TGGGAGTACT TTTCCAGGAT CGTAACAACT TGCGTGTTAA ATCGGTCAGC    5280

GTCAGTCAGT CCGTCAGCAA AAGCGAAGGC TTCAATACCC CAGCGCTGTT ACTGGGGACG    5340

AGCAACAGCG CTGCTATGAG CATGGAGCGC AACATCGGAA CCATTAATTT TAAATACGGC    5400

CAGGATCAGA ACACCCCACG GCGATTTACC CTGGAGGGTG GAATAGCTCA GGCTAATCCG    5460

CAGGTCGCAT CTGCGCTTAC TGATTTGAAG AAGGAAGGGC TGGAAATGAA GAGCTAA       5517
```

This DNA molecule is known as the dspE gene for *Erwinia amylovora*. This isolated DNA molecule of the present invention encodes a protein or polypeptide which elicits a plant pathogen's hypersensitive response having an amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 28 as follows:

```
Met Glu Leu Lys Ser Leu Gly Thr Glu His Lys Ala Ala Val His Thr
1               5                  10                  15

Ala Ala His Asn Pro Val Gly His Gly Val Ala Leu Gln Gln Gly Ser
            20                  25                  30

Ser Ser Ser Ser Pro Gln Asn Ala Ala Ala Ser Leu Ala Ala Glu Gly
        35                  40                  45

Lys Asn Arg Gly Lys Met Pro Arg Ile His Gln Pro Ser Thr Ala Ala
    50                  55                  60

Asp Gly Ile Ser Ala Ala His Gln Gln Lys Lys Ser Phe Ser Leu Arg
65                  70                  75                  80

Gly Cys Leu Gly Thr Lys Lys Phe Ser Arg Ser Ala Pro Gln Gly Gln
                85                  90                  95

Pro Gly Thr Thr His Ser Lys Gly Ala Thr Leu Arg Asp Leu Leu Ala
            100                 105                 110

Arg Asp Asp Gly Glu Thr Gln His Glu Ala Ala Ala Pro Asp Ala Ala
        115                 120                 125

Arg Leu Thr Arg Ser Gly Gly Val Lys Arg Arg Asn Met Asp Asp Met
    130                 135                 140

Ala Gly Arg Pro Met Val Lys Gly Gly Ser Gly Glu Asp Lys Val Pro
145                 150                 155                 160
```

Appendix A

Version With Markings to Show Changes Made


```
Thr Gln Gln Lys Arg His Gln Leu Asn Asn Phe Gly Gln Met Arg Gln
                165                 170                 175

Thr Met Leu Ser Lys Met Ala His Pro Ala Ser Ala Asn Ala Gly Asp
            180                 185                 190

Arg Leu Gln His Ser Pro Pro His Ile Pro Gly Ser His His Glu Ile
        195                 200                 205

Lys Glu Glu Pro Val Gly Ser Thr Ser Lys Ala Thr Thr Ala His Ala
    210                 215                 220

Asp Arg Val Glu Ile Ala Gln Glu Asp Asp Asp Ser Glu Phe Gln Gln
225                 230                 235                 240

Leu His Gln Gln Arg Leu Ala Arg Glu Arg Glu Asn Pro Pro Gln Pro
                245                 250                 255

Pro Lys Leu Gly Val Ala Thr Pro Ile Ser Ala Arg Phe Gln Pro Lys
            260                 265                 270

Leu Thr Ala Val Ala Glu Ser Val Leu Glu Gly Thr Asp Thr Thr Gln
        275                 280                 285

Ser Pro Leu Lys Pro Gln Ser Met Leu Lys Gly Ser Gly Ala Gly Val
    290                 295                 300

Thr Pro Leu Ala Val Thr Leu Asp Lys Gly Lys Leu Gln Leu Ala Pro
305                 310                 315                 320

Asp Asn Pro Pro Ala Leu Asn Thr Leu Leu Lys Gln Thr Leu Gly Lys
                325                 330                 335

Asp Thr Gln His Tyr Leu Ala His His Ala Ser Ser Asp Gly Ser Gln
            340                 345                 350

His Leu Leu Leu Asp Asn Lys Gly His Leu Phe Asp Ile Lys Ser Thr
        355                 360                 365

Ala Thr Ser Tyr Ser Val Leu His Asn Ser His Pro Gly Glu Ile Lys
    370                 375                 380

Gly Lys Leu Ala Gln Ala Gly Thr Gly Ser Val Ser Val Asp Gly Lys
385                 390                 395                 400

Ser Gly Lys Ile Ser Leu Gly Ser Gly Thr Gln Ser His Asn Lys Thr
                405                 410                 415

Met Leu Ser Gln Pro Gly Glu Ala His Arg Ser Leu Leu Thr Gly Ile
            420                 425                 430

Trp Gln His Pro Ala Gly Ala Ala Arg Pro Gln Gly Glu Ser Ile Arg
        435                 440                 445

Leu His Asp Asp Lys Ile His Ile Leu His Pro Glu Leu Gly Val Trp
    450                 455                 460

Gln Ser Ala Asp Lys Asp Thr His Ser Gln Leu Ser Arg Gln Ala Asp
465                 470                 475                 480

Gly Lys Leu Tyr Ala Leu Lys Asp Asn Arg Thr Leu Gln Asn Leu Ser
                485                 490                 495
```

Appendix A

Version With Markings to Show Changes Made


```
Asp Asn Lys Ser Ser Glu Lys Leu Val Asp Lys Ile Lys Ser Tyr Ser
            500                 505                 510

Val Asp Gln Arg Gly Gln Val Ala Ile Leu Thr Asp Thr Pro Gly Arg
        515                 520                 525

His Lys Met Ser Ile Met Pro Ser Leu Asp Ala Ser Pro Glu Ser His
    530                 535                 540

Ile Ser Leu Ser Leu His Phe Ala Asp Ala His Gln Gly Leu Leu His
545                 550                 555                 560

Gly Lys Ser Glu Leu Glu Ala Gln Ser Val Ala Ile Ser His Gly Arg
                565                 570                 575

Leu Val Val Ala Asp Ser Glu Gly Lys Leu Phe Ser Ala Ala Ile Pro
            580                 585                 590

Lys Gln Gly Asp Gly Asn Glu Leu Lys Met Lys Ala Met Pro Gln His
        595                 600                 605

Ala Leu Asp Glu His Phe Gly His Asp His Gln Ile Ser Gly Phe Phe
    610                 615                 620

His Asp Asp His Gly Gln Leu Asn Ala Leu Val Lys Asn Asn Phe Arg
625                 630                 635                 640

Gln Gln His Ala Cys Pro Leu Gly Asn Asp His Gln Phe His Pro Gly
                645                 650                 655

Trp Asn Leu Thr Asp Ala Leu Val Ile Asp Asn Gln Leu Gly Leu His
            660                 665                 670

His Thr Asn Pro Glu Pro His Glu Ile Leu Asp Met Gly His Leu Gly
        675                 680                 685

Ser Leu Ala Leu Gln Glu Gly Lys Leu His Tyr Phe Asp Gln Leu Thr
    690                 695                 700

Lys Gly Trp Thr Gly Ala Glu Ser Asp Cys Lys Gln Leu Lys Lys Gly
705                 710                 715                 720

Leu Asp Gly Ala Ala Tyr Leu Leu Lys Asp Gly Glu Val Lys Arg Leu
                725                 730                 735

Asn Ile Asn Gln Ser Thr Ser Ser Ile Lys His Gly Thr Glu Asn Val
            740                 745                 750

Phe Ser Leu Pro His Val Arg Asn Lys Pro Glu Pro Gly Asp Ala Leu
        755                 760                 765

Gln Gly Leu Asn Lys Asp Asp Lys Ala Gln Ala Met Ala Val Ile Gly
    770                 775                 780

Val Asn Lys Tyr Leu Ala Leu Thr Glu Lys Gly Asp Ile Arg Ser Phe
785                 790                 795                 800

Gln Ile Lys Pro Gly Thr Gln Gln Leu Glu Arg Pro Ala Gln Thr Leu
                805                 810                 815
```

```
Ser Arg Glu Gly Ile Ser Gly Glu Leu Lys Asp Ile His Val Asp His
            820                 825                 830

Lys Gln Asn Leu Tyr Ala Leu Thr His Glu Gly Glu Val Phe His Gln
        835                 840                 845

Pro Arg Glu Ala Trp Gln Asn Gly Ala Glu Ser Ser Ser Trp His Lys
    850                 855                 860

Leu Ala Leu Pro Gln Ser Glu Ser Lys Leu Lys Ser Leu Asp Met Ser
865                 870                 875                 880

His Glu His Lys Pro Ile Ala Thr Phe Glu Asp Gly Ser Gln His Gln
                885                 890                 895

Leu Lys Ala Gly Gly Trp His Ala Tyr Ala Ala Pro Glu Arg Gly Pro
            900                 905                 910

Leu Ala Val Gly Thr Ser Gly Ser Gln Thr Val Phe Asn Arg Leu Met
        915                 920                 925

Gln Gly Val Lys Gly Lys Val Ile Pro Gly Ser Gly Leu Thr Val Lys
    930                 935                 940

Leu Ser Ala Gln Thr Gly Gly Met Thr Gly Ala Glu Gly Arg Lys Val
945                 950                 955                 960

Ser Ser Lys Phe Ser Glu Arg Ile Arg Ala Tyr Ala Phe Asn Pro Thr
                965                 970                 975

Met Ser Thr Pro Arg Pro Ile Lys Asn Ala Ala Tyr Ala Thr Gln His
            980                 985                 990

Gly Trp Gln Gly Arg Glu Gly Leu Lys Pro Leu Tyr Glu Met Gln Gly
        995                 1000                1005

Ala Leu Ile Lys Gln Leu Asp Ala His Asn Val Arg His Asn Ala Pro
    1010                1015                1020

Gln Pro Asp Leu Gln Ser Lys Leu Glu Thr Leu Asp Leu Gly Glu His
1025                1030                1035                1040

Gly Ala Glu Leu Leu Asn Asp Met Lys Arg Phe Arg Asp Glu Leu Glu
                1045                1050                1055

Gln Ser Ala Thr Arg Ser Val Thr Val Leu Gly Gln His Gln Gly Val
            1060                1065                1070

Leu Lys Ser Asn Gly Glu Ile Asn Ser Glu Phe Lys Pro Ser Pro Gly
        1075                1080                1085

Lys Ala Leu Val Gln Ser Phe Asn Val Asn Arg Ser Gly Gln Asp Leu
    1090                1095                1100

Ser Lys Ser Leu Gln Gln Ala Val His Ala Thr Pro Pro Ser Ala Glu
1105                1110                1115                1120

Ser Lys Leu Gln Ser Met Leu Gly His Phe Val Ser Ala Gly Val Asp
                1125                1130                1135

Met Ser His Gln Lys Gly Glu Ile Pro Leu Gly Arg Gln Arg Asp Pro
            1140                1145                1150
```

Appendix A

Version With Markings to Show Changes Made


```
Asn Asp Lys Thr Ala Leu Thr Lys Ser Arg Leu Ile Leu Asp Thr Val
        1155                1160                1165

Thr Ile Gly Glu Leu His Glu Leu Ala Asp Lys Ala Lys Leu Val Ser
    1170                1175                1180

Asp His Lys Pro Asp Ala Asp Gln Ile Lys Gln Leu Arg Gln Gln Phe
1185                1190                1195                1200

Asp Thr Leu Arg Glu Lys Arg Tyr Glu Ser Asn Pro Val Lys His Tyr
                1205                1210                1215

Thr Asp Met Gly Phe Thr His Asn Lys Ala Leu Glu Ala Asn Tyr Asp
            1220                1225                1230

Ala Val Lys Ala Phe Ile Asn Ala Phe Lys Lys Glu His His Gly Val
        1235                1240                1245

Asn Leu Thr Thr Arg Thr Val Leu Glu Ser Gln Gly Ser Ala Glu Leu
    1250                1255                1260

Ala Lys Lys Leu Lys Asn Thr Leu Leu Ser Leu Asp Ser Gly Glu Ser
1265                1270                1275                1280

Met Ser Phe Ser Arg Ser Tyr Gly Gly Gly Val Ser Thr Val Phe Val
                1285                1290                1295

Pro Thr Leu Ser Lys Lys Val Pro Val Pro Val Ile Pro Gly Ala Gly
            1300                1305                1310

Ile Thr Leu Asp Arg Ala Tyr Asn Leu Ser Phe Ser Arg Thr Ser Gly
        1315                1320                1325

Gly Leu Asn Val Ser Phe Gly Arg Asp Gly Gly Val Ser Gly Asn Ile
    1330                1335                1340

Met Val Ala Thr Gly His Asp Val Met Pro Tyr Met Thr Gly Lys Lys
1345                1350                1355                1360

Thr Ser Ala Gly Asn Ala Ser Asp Trp Leu Ser Ala Lys His Lys Ile
                1365                1370                1375

Ser Pro Asp Leu Arg Ile Gly Ala Ala Val Ser Gly Thr Leu Gln Gly
            1380                1385                1390

Thr Leu Gln Asn Ser Leu Lys Phe Lys Leu Thr Glu Asp Glu Leu Pro
        1395                1400                1405

Gly Phe Ile His Gly Leu Thr His Gly Thr Leu Thr Pro Ala Glu Leu
    1410                1415                1420

Leu Gln Lys Gly Ile Glu His Gln Met Lys Gln Gly Ser Lys Leu Thr
1425                1430                1435                1440

Phe Ser Val Asp Thr Ser Ala Asn Leu Asp Leu Arg Ala Gly Ile Asn
                1445                1450                1455

Leu Asn Glu Asp Gly Ser Lys Pro Asn Gly Val Thr Ala Arg Val Ser
            1460                1465                1470
```

Appendix A

Version With Markings to Show Changes Made


```
Ala Gly Leu Ser Ala Ser Ala Asn Leu Ala Ala Gly Ser Arg Glu Arg
        1475                1480                1485

Ser Thr Thr Ser Gly Gln Phe Gly Ser Thr Thr Ser Ala Ser Asn Asn
    1490                1495                1500

Arg Pro Thr Phe Leu Asn Gly Val Gly Ala Gly Ala Asn Leu Thr Ala
1505                1510                1515                1520

Ala Leu Gly Val Ala His Ser Ser Thr His Glu Gly Lys Pro Val Gly
                1525                1530                1535

Ile Phe Pro Ala Phe Thr Ser Thr Asn Val Ser Ala Ala Leu Ala Leu
            1540                1545                1550

Asp Asn Arg Thr Ser Gln Ser Ile Ser Leu Glu Leu Lys Arg Ala Glu
        1555                1560                1565

Pro Val Thr Ser Asn Asp Ile Ser Glu Leu Thr Ser Thr Leu Gly Lys
    1570                1575                1580

His Phe Lys Asp Ser Ala Thr Thr Lys Met Leu Ala Ala Leu Lys Glu
1585                1590                1595                1600

Leu Asp Asp Ala Lys Pro Ala Glu Gln Leu His Ile Leu Gln Gln His
                1605                1610                1615

Phe Ser Ala Lys Asp Val Val Gly Asp Glu Arg Tyr Glu Ala Val Arg
            1620                1625                1630

Asn Leu Lys Lys Leu Val Ile Arg Gln Gln Ala Ala Asp Ser His Ser
        1635                1640                1645

Met Glu Leu Gly Ser Ala Ser His Ser Thr Thr Tyr Asn Asn Leu Ser
    1650                1655                1660

Arg Ile Asn Asn Asp Gly Ile Val Glu Leu Leu His Lys His Phe Asp
1665                1670                1675                1680

Ala Ala Leu Pro Ala Ser Ser Ala Lys Arg Leu Gly Glu Met Met Asn
                1685                1690                1695

Asn Asp Pro Ala Leu Lys Asp Ile Ile Lys Gln Leu Gln Ser Thr Pro
            1700                1705                1710

Phe Ser Ser Ala Ser Val Ser Met Glu Leu Lys Asp Gly Leu Arg Glu
        1715                1720                1725

Gln Thr Glu Lys Ala Ile Leu Asp Gly Lys Val Gly Arg Glu Glu Val
    1730                1735                1740

Gly Val Leu Phe Gln Asp Arg Asn Asn Leu Arg Val Lys Ser Val Ser
1745                1750                1755                1760

Val Ser Gln Ser Val Ser Lys Ser Glu Gly Phe Asn Thr Pro Ala Leu
                1765                1770                1775

Leu Leu Gly Thr Ser Asn Ser Ala Ala Met Ser Met Glu Arg Asn Ile
            1780                1785                1790

Gly Thr Ile Asn Phe Lys Tyr Gly Gln Asp Gln Asn Thr Pro Arg Arg
        1795                1800                1805
```

```
Phe Thr Leu Glu Gly Gly Ile Ala Gln Ala Asn Pro Gln Val Ala Ser
    1810                1815                1820

Ala Leu Thr Asp Leu Lys Lys Glu Gly Leu Glu Met Lys Ser
1825                1830                1835
```

This protein or polypeptide is about 198 kDa and has a pI of 8.98.

Please replace the paragraph beginning on page 22, line 25, and ending on page 23, line 17, with the following replacement paragraph:

The present invention relates to an isolated DNA molecule having a nucleotide sequence of [SEQ. ID. No.] SEQ ID NO: 29 as follows:

```
ATGACATCGT CACAGCAGCG GGTTGAAAGG TTTTTACAGT ATTTCTCCGC CGGGTGTAAA      60

ACGCCCATAC ATCTGAAAGA CGGGGTGTGC GCCCTGTATA ACGAACAAGA TGAGGAGGCG     120

GCGGTGCTGG AAGTACCGCA ACACAGCGAC AGCCTGTTAC TACACTGCCG AATCATTGAG     180

GCTGACCCAC AAACTTCAAT AACCCTGTAT TCGATGCTAT TACAGCTGAA TTTTGAAATG     240

GCGGCCATGC GCGGCTGTTG GCTGGCGCTG GATGAACTGC ACAACGTGCG TTTATGTTTT     300

CAGCAGTCGC TGGAGCATCT GGATGAAGCA AGTTTTAGCG ATATCGTTAG CGGCTTCATC     360

GAACATGCGG CAGAAGTGCG TGAGTATATA GCGCAATTAG ACGAGAGTAG CGCGGCATAA     420
```

This is known as the dspF gene. This isolated DNA molecule of the present invention encodes a hypersensitive response elicitor protein or polypeptide having an amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 30 as follows:

```
Met Thr Ser Ser Gln Gln Arg Val Glu Arg Phe Leu Gln Tyr Phe Ser
1               5                   10                  15

Ala Gly Cys Lys Thr Pro Ile His Leu Lys Asp Gly Val Cys Ala Leu
            20                  25                  30

Tyr Asn Glu Gln Asp Glu Glu Ala Ala Val Leu Glu Val Pro Gln His
        35                  40                  45

Ser Asp Ser Leu Leu Leu His Cys Arg Ile Ile Glu Ala Asp Pro Gln
    50                  55                  60

Thr Ser Ile Thr Leu Tyr Ser Met Leu Leu Gln Leu Asn Phe Glu Met
65                  70                  75                  80

Ala Ala Met Arg Gly Cys Trp Leu Ala Leu Asp Glu Leu His Asn Val
                85                  90                  95
```

```
Arg Leu Cys Phe Gln Gln Ser Leu Glu His Leu Asp Glu Ala Ser Phe
            100                 105                 110

Ser Asp Ile Val Ser Gly Phe Ile Glu His Ala Ala Glu Val Arg Glu
        115                 120                 125

Tyr Ile Ala Gln Leu Asp Glu Ser Ser Ala Ala
    130                 135
```

This protein or polypeptide is about 16 kDa and has a pI of 4.45.

Please replace the paragraph beginning on page 23, line 18, and ending on page 25, line 13, with the following replacement paragraph:

The hypersensitive response elicitor polypeptide or protein derived from *Pseudomonas syringae* has an amino acid sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 31 as follows:

```
Met Gln Ser Leu Ser Leu Asn Ser Ser Ser Leu Gln Thr Pro Ala Met
1               5                   10                  15

Ala Leu Val Leu Val Arg Pro Glu Ala Glu Thr Thr Gly Ser Thr Ser
            20                  25                  30

Ser Lys Ala Leu Gln Glu Val Val Val Lys Leu Ala Glu Glu Leu Met
        35                  40                  45

Arg Asn Gly Gln Leu Asp Asp Ser Ser Pro Leu Gly Lys Leu Leu Ala
    50                  55                  60

Lys Ser Met Ala Ala Asp Gly Lys Ala Gly Gly Gly Ile Glu Asp Val
65                  70                  75                  80

Ile Ala Ala Leu Asp Lys Leu Ile His Glu Lys Leu Gly Asp Asn Phe
                85                  90                  95

Gly Ala Ser Ala Asp Ser Ala Ser Gly Thr Gly Gln Gln Asp Leu Met
            100                 105                 110

Thr Gln Val Leu Asn Gly Leu Ala Lys Ser Met Leu Asp Asp Leu Leu
        115                 120                 125

Thr Lys Gln Asp Gly Gly Thr Ser Phe Ser Glu Asp Asp Met Pro Met
    130                 135                 140

Leu Asn Lys Ile Ala Gln Phe Met Asp Asp Asn Pro Ala Gln Phe Pro
145                 150                 155                 160
```

Appendix A

Version With Markings to Show Changes Made


```
Lys Pro Asp Ser Gly Ser Trp Val Asn Glu Leu Lys Glu Asp Asn Phe
                165                 170                 175

Leu Asp Gly Asp Glu Thr Ala Ala Phe Arg Ser Ala Leu Asp Ile Ile
            180                 185                 190

Gly Gln Gln Leu Gly Asn Gln Gln Ser Asp Ala Gly Ser Leu Ala Gly
        195                 200                 205

Thr Gly Gly Gly Leu Gly Thr Pro Ser Ser Phe Ser Asn Asn Ser Ser
    210                 215                 220

Val Met Gly Asp Pro Leu Ile Asp Ala Asn Thr Gly Pro Gly Asp Ser
225                 230                 235                 240

Gly Asn Thr Arg Gly Glu Ala Gly Gln Leu Ile Gly Glu Leu Ile Asp
                245                 250                 255

Arg Gly Leu Gln Ser Val Leu Ala Gly Gly Gly Leu Gly Thr Pro Val
            260                 265                 270

Asn Thr Pro Gln Thr Gly Thr Ser Ala Asn Gly Gly Gln Ser Ala Gln
        275                 280                 285

Asp Leu Asp Gln Leu Leu Gly Gly Leu Leu Leu Lys Gly Leu Glu Ala
    290                 295                 300

Thr Leu Lys Asp Ala Gly Gln Thr Gly Thr Asp Val Gln Ser Ser Ala
305                 310                 315                 320

Ala Gln Ile Ala Thr Leu Leu Val Ser Thr Leu Leu Gln Gly Thr Arg
                325                 330                 335

Asn Gln Ala Ala Ala
            340
```

This hypersensitive response elicitor polypeptide or protein has a molecular weight of 34-35 kDa. It is rich in glycine (about 13.5%) and lacks cysteine and tyrosine. Further information about the hypersensitive response elicitor derived from *Pseudomonas syringae* is found in He, S. Y., H. C. Huang, and A. Collmer, "*Pseudomonas syringae* pv. *syringae* $Harpin_{Pss}$: a Protein that is Secreted via the Hrp Pathway and Elicits the Hypersensitive Response in Plants," Cell 73:1255-1266 (1993), which is hereby incorporated by reference. The DNA molecule encoding the hypersensitive response elicitor from *Pseudomonas syringae* has a nucleotide sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 32 as follows:

```
ATGCAGAGTC TCAGTCTTAA CAGCAGCTCG CTGCAAACCC CGGCAATGGC CCTTGTCCTG      60

GTACGTCCTG AAGCCGAGAC GACTGGCAGT ACGTCGAGCA AGGCGCTTCA GGAAGTTGTC     120
```

```
GTGAAGCTGG CCGAGGAACT GATGCGCAAT GGTCAACTCG ACGACAGCTC GCCATTGGGA     180

AAACTGTTGG CCAAGTCGAT GGCCGCAGAT GGCAAGGCGG GCGGCGGTAT TGAGGATGTC     240

ATCGCTGCGC TGGACAAGCT GATCCATGAA AAGCTCGGTG ACAACTTCGG CGCGTCTGCG     300

GACAGCGCCT CGGGTACCGG ACAGCAGGAC CTGATGACTC AGGTGCTCAA TGGCCTGGCC     360

AAGTCGATGC TCGATGATCT TCTGACCAAG CAGGATGGCG GGACAAGCTT CTCCGAAGAC     420

GATATGCCGA TGCTGAACAA GATCGCGCAG TTCATGGATG ACAATCCCGC ACAGTTTCCC     480

AAGCCGGACT CGGGCTCCTG GGTGAACGAA CTCAAGGAAG ACAACTTCCT TGATGGCGAC     540

GAAACGGCTG CGTTCCGTTC GGCACTCGAC ATCATTGGCC AGCAACTGGG TAATCAGCAG     600

AGTGACGCTG GCAGTCTGGC AGGGACGGGT GGAGGTCTGG GCACTCCGAG CAGTTTTTCC     660

AACAACTCGT CCGTGATGGG TGATCCGCTG ATCGACGCCA ATACCGGTCC CGGTGACAGC     720

GGCAATACCC GTGGTGAAGC GGGGCAACTG ATCGGCGAGC TTATCGACCG TGGCCTGCAA     780

TCGGTATTGG CCGGTGGTGG ACTGGGCACA CCCGTAAACA CCCCGCAGAC CGGTACGTCG     840

GCGAATGGCG GACAGTCCGC TCAGGATCTT GATCAGTTGC TGGGCGGCTT GCTGCTCAAG     900

GGCCTGGAGG CAACGCTCAA GGATGCCGGG CAAACAGGCA CCGACGTGCA GTCGAGCGCT     960

GCGCAAATCG CCACCTTGCT GGTCAGTACG CTGCTGCAAG GCACCCGCAA TCAGGCTGCA    1020

GCCTGA                                                               1026
```

Please replace the paragraph beginning on page 25, line 15, and ending on page 28, line 6, with the following replacement paragraph:

Another potentially suitable hypersensitive response elicitor from *Pseudomonas syringae* is disclosed in U.S. Patent Application Serial No. 09/120,817, which is hereby incorporated by reference. The protein has a nucleotide sequence of [SEQ. ID. No.] SEQ ID NO: 33 as follows:

```
TCCACTTCGC TGATTTTGAA ATTGGCAGAT TCATAGAAAC GTTCAGGTGT GGAAATCAGG      60

CTGAGTGCGC AGATTTCGTT GATAAGGGTG TGGTACTGGT CATTGTTGGT CATTTCAAGG     120

CCTCTGAGTG CGGTGCGGAG CAATACCAGT CTTCCTGCTG GCGTGTGCAC ACTGAGTCGC     180

AGGCATAGGC ATTTCAGTTC CTTGCGTTGG TTGGGCATAT AAAAAAAGGA ACTTTTAAAA     240

ACAGTGCAAT GAGATGCCGG CAAAACGGGA ACCGGTCGCT GCGCTTTGCC ACTCACTTCG     300
```

```
AGCAAGCTCA ACCCCAAACA TCCACATCCC TATCGAACGG ACAGCGATAC GGCCACTTGC     360
TCTGGTAAAC CCTGGAGCTG GCGTCGGTCC AATTGCCCAC TTAGCGAGGT AACGCAGCAT     420
GAGCATCGGC ATCACACCCC GGCCGCAACA GACCACCACG CCACTCGATT TTTCGGCGCT     480
AAGCGGCAAG AGTCCTCAAC CAAACACGTT CGGCGAGCAG AACACTCAGC AAGCGATCGA     540
CCCGAGTGCA CTGTTGTTCG GCAGCGACAC ACAGAAAGAC GTCAACTTCG GCACGCCCGA     600
CAGCACCGTC CAGAATCCGC AGGACGCCAG CAAGCCCAAC GACAGCCAGT CCAACATCGC     660
TAAATTGATC AGTGCATTGA TCATGTCGTT GCTGCAGATG CTCACCAACT CCAATAAAAA     720
GCAGGACACC AATCAGGAAC AGCCTGATAG CCAGGCTCCT TTCCAGAACA ACGGCGGGCT     780
CGGTACACCG TCGGCCGATA GCGGGGGCGG CGGTACACCG GATGCGACAG GTGGCGGCGG     840
CGGTGATACG CCAAGCGCAA CAGGCGGTGG CGGCGGTGAT ACTCCGACCG CAACAGGCGG     900
TGGCGGCAGC GGTGGCGGCG GCACACCCAC TGCAACAGGT GGCGGCAGCG GTGGCACACC     960
CACTGCAACA GGCGGTGGCG AGGGTGGCGT AACACCGCAA ATCACTCCGC AGTTGGCCAA    1020
CCCTAACCGT ACCTCAGGTA CTGGCTCGGT GTCGGACACC GCAGGTTCTA CCGAGCAAGC    1080
CGGCAAGATC AATGTGGTGA AAGACACCAT CAAGGTCGGC GCTGGCGAAG TCTTTGACGG    1140
CCACGGCGCA ACCTTCACTG CCGACAAATC TATGGGTAAC GGAGACCAGG GCGAAAATCA    1200
GAAGCCCATG TTCGAGCTGG CTGAAGGCGC TACGTTGAAG AATGTGAACC TGGGTGAGAA    1260
CGAGGTCGAT GGCATCCACG TGAAAGCCAA AAACGCTCAG GAAGTCACCA TTGACAACGT    1320
GCATGCCCAG AACGTCGGTG AAGACCTGAT TACGGTCAAA GGCGAGGGAG GCGCAGCGGT    1380
CACTAATCTG AACATCAAGA ACAGCAGTGC CAAAGGTGCA GACGACAAGG TTGTCCAGCT    1440
CAACGCCAAC ACTCACTTGA AAATCGACAA CTTCAAGGCC GACGATTTCG GCACGATGGT    1500
TCGCACCAAC GGTGGCAAGC AGTTTGATGA CATGAGCATC GAGCTGAACG GCATCGAAGC    1560
TAACCACGGC AAGTTCGCCC TGGTGAAAAG CGACAGTGAC GATCTGAAGC TGGCAACGGG    1620
CAACATCGCC ATGACCGACG TCAAACACGC CTACGATAAA ACCCAGGCAT CGACCCAACA    1680
CACCGAGCTT TGAATCCAGA CAAGTAGCTT GAAAAAAGGG GGTGGACTC                1729
```

This DNA molecule is known as the dspE gene for *Pseudomonas syringae*. This isolated DNA molecule of the present invention encodes a protein or polypeptide which elicits a plant pathogen's hypersensitive response having an amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 34 as follows:

```
Met Ser Ile Gly Ile Thr Pro Arg Pro Gln Gln Thr Thr Thr Pro Leu
1               5                  10                  15
```

Appendix A

Version With Markings to Show Changes Made


```
Asp Phe Ser Ala Leu Ser Gly Lys Ser Pro Gln Pro Asn Thr Phe Gly
            20                  25                  30

Glu Gln Asn Thr Gln Gln Ala Ile Asp Pro Ser Ala Leu Leu Phe Gly
        35                  40                  45

Ser Asp Thr Gln Lys Asp Val Asn Phe Gly Thr Pro Asp Ser Thr Val
    50                  55                  60

Gln Asn Pro Gln Asp Ala Ser Lys Pro Asn Asp Ser Gln Ser Asn Ile
65                  70                  75                  80

Ala Lys Leu Ile Ser Ala Leu Ile Met Ser Leu Leu Gln Met Leu Thr
                85                  90                  95

Asn Ser Asn Lys Lys Gln Asp Thr Asn Gln Glu Gln Pro Asp Ser Gln
            100                 105                 110

Ala Pro Phe Gln Asn Asn Gly Gly Leu Gly Thr Pro Ser Ala Asp Ser
        115                 120                 125

Gly Gly Gly Gly Thr Pro Asp Ala Thr Gly Gly Gly Gly Gly Asp Thr
    130                 135                 140

Pro Ser Ala Thr Gly Gly Gly Gly Gly Asp Thr Pro Thr Ala Thr Gly
145                 150                 155                 160

Gly Gly Gly Ser Gly Gly Gly Gly Thr Pro Thr Ala Thr Gly Gly Gly
                165                 170                 175

Ser Gly Gly Thr Pro Thr Ala Thr Gly Gly Gly Glu Gly Gly Val Thr
            180                 185                 190

Pro Gln Ile Thr Pro Gln Leu Ala Asn Pro Asn Arg Thr Ser Gly Thr
        195                 200                 205

Gly Ser Val Ser Asp Thr Ala Gly Ser Thr Glu Gln Ala Gly Lys Ile
    210                 215                 220

Asn Val Val Lys Asp Thr Ile Lys Val Gly Ala Gly Glu Val Phe Asp
225                 230                 235                 240

Gly His Gly Ala Thr Phe Thr Ala Asp Lys Ser Met Gly Asn Gly Asp
                245                 250                 255

Gln Gly Glu Asn Gln Lys Pro Met Phe Glu Leu Ala Glu Gly Ala Thr
            260                 265                 270

Leu Lys Asn Val Asn Leu Gly Glu Asn Glu Val Asp Gly Ile His Val
        275                 280                 285

Lys Ala Lys Asn Ala Gln Glu Val Thr Ile Asp Asn Val His Ala Gln
    290                 295                 300

Asn Val Gly Glu Asp Leu Ile Thr Val Lys Gly Glu Gly Gly Ala Ala
305                 310                 315                 320
```

```
Val Thr Asn Leu Asn Ile Lys Asn Ser Ser Ala Lys Gly Ala Asp Asp
                325                 330                 335

Lys Val Val Gln Leu Asn Ala Asn Thr His Leu Lys Ile Asp Asn Phe
            340                 345                 350

Lys Ala Asp Asp Phe Gly Thr Met Val Arg Thr Asn Gly Gly Lys Gln
        355                 360                 365

Phe Asp Asp Met Ser Ile Glu Leu Asn Gly Ile Glu Ala Asn His Gly
    370                 375                 380

Lys Phe Ala Leu Val Lys Ser Asp Ser Asp Asp Leu Lys Leu Ala Thr
385                 390                 395                 400

Gly Asn Ile Ala Met Thr Asp Val Lys His Ala Tyr Asp Lys Thr Gln
                405                 410                 415

Ala Ser Thr Gln His Thr Glu Leu
            420
```

This protein or polypeptide is about 42.9 kDa.

Please replace the paragraph beginning on page 28, line 8, and ending on page 30, line 11, with the following replacement paragraph:

The hypersensitive response elicitor polypeptide or protein derived from *Pseudomonas solanacearum* has an amino acid sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 35 as follows:

```
Met Ser Val Gly Asn Ile Gln Ser Pro Ser Asn Leu Pro Gly Leu Gln
1               5                   10                  15

Asn Leu Asn Leu Asn Thr Asn Thr Asn Ser Gln Gln Ser Gly Gln Ser
            20                  25                  30

Val Gln Asp Leu Ile Lys Gln Val Glu Lys Asp Ile Leu Asn Ile Ile
        35                  40                  45

Ala Ala Leu Val Gln Lys Ala Ala Gln Ser Ala Gly Gly Asn Thr Gly
    50                  55                  60

Asn Thr Gly Asn Ala Pro Ala Lys Asp Gly Asn Ala Asn Ala Gly Ala
65                  70                  75                  80

Asn Asp Pro Ser Lys Asn Asp Pro Ser Lys Ser Gln Ala Pro Gln Ser
                85                  90                  95
```

Appendix A

Version With Markings to Show Changes Made


```
Ala Asn Lys Thr Gly Asn Val Asp Asp Ala Asn Asn Gln Asp Pro Met
            100                 105                 110

Gln Ala Leu Met Gln Leu Leu Glu Asp Leu Val Lys Leu Leu Lys Ala
        115                 120                 125

Ala Leu His Met Gln Gln Pro Gly Gly Asn Asp Lys Gly Asn Gly Val
    130                 135                 140

Gly Gly Ala Asn Gly Ala Lys Gly Ala Gly Gly Gln Gly Gly Leu Ala
145                 150                 155                 160

Glu Ala Leu Gln Glu Ile Glu Gln Ile Leu Ala Gln Leu Gly Gly Gly
                165                 170                 175

Gly Ala Gly Ala Gly Gly Ala Gly Gly Gly Val Gly Gly Ala Gly Gly
            180                 185                 190

Ala Asp Gly Gly Ser Gly Ala Gly Gly Ala Gly Gly Ala Asn Gly Ala
        195                 200                 205

Asp Gly Gly Asn Gly Val Asn Gly Asn Gln Ala Asn Gly Pro Gln Asn
    210                 215                 220

Ala Gly Asp Val Asn Gly Ala Asn Gly Ala Asp Asp Gly Ser Glu Asp
225                 230                 235                 240

Gln Gly Gly Leu Thr Gly Val Leu Gln Lys Leu Met Lys Ile Leu Asn
                245                 250                 255

Ala Leu Val Gln Met Met Gln Gln Gly Gly Leu Gly Gly Gly Asn Gln
            260                 265                 270

Ala Gln Gly Gly Ser Lys Gly Ala Gly Asn Ala Ser Pro Ala Ser Gly
        275                 280                 285

Ala Asn Pro Gly Ala Asn Gln Pro Gly Ser Ala Asp Asp Gln Ser Ser
    290                 295                 300

Gly Gln Asn Asn Leu Gln Ser Gln Ile Met Asp Val Val Lys Glu Val
305                 310                 315                 320

Val Gln Ile Leu Gln Gln Met Leu Ala Ala Gln Asn Gly Gly Ser Gln
                325                 330                 335

Gln Ser Thr Ser Thr Gln Pro Met
            340
```

It is encoded by a DNA molecule having a nucleotide sequence corresponding [SEQ. ID. No.] to SEQ ID NO: 36 as follows:

```
ATGTCAGTCG GAAACATCCA GAGCCCGTCG AACCTCCCGG GTCTGCAGAA CCTGAACCTC      60

AACACCAACA CCAACAGCCA GCAATCGGGC CAGTCCGTGC AAGACCTGAT CAAGCAGGTC     120
```

```
GAGAAGGACA TCCTCAACAT CATCGCAGCC CTCGTGCAGA AGGCCGCACA GTCGGCGGGC     180

GGCAACACCG GTAACACCGG CAACGCGCCG GCGAAGGACG GCAATGCCAA CGCGGGCGCC     240

AACGACCCGA GCAAGAACGA CCCGAGCAAG AGCCAGGCTC CGCAGTCGGC CAACAAGACC     300

GGCAACGTCG ACGACGCCAA CAACCAGGAT CCGATGCAAG CGCTGATGCA GCTGCTGGAA     360

GACCTGGTGA AGCTGCTGAA GGCGGCCCTG CACATGCAGC AGCCCGGCGG CAATGACAAG     420

GGCAACGGCG TGGGCGGTGC CAACGGCGCC AAGGGTGCCG GCGGCCAGGG CGGCCTGGCC     480

GAAGCGCTGC AGGAGATCGA GCAGATCCTC GCCCAGCTCG GCGGCGGCGG TGCTGGCGCC     540

GGCGGCGCGG GTGGCGGTGT CGGCGGTGCT GGTGGCGCGG ATGGCGGCTC CGGTGCGGGT     600

GGCGCAGGCG GTGCGAACGG CGCCGACGGC GGCAATGGCG TGAACGGCAA CCAGGCGAAC     660

GGCCCGCAGA ACGCAGGCGA TGTCAACGGT GCCAACGGCG CGGATGACGG CAGCGAAGAC     720

CAGGGCGGCC TCACCGGCGT GCTGCAAAAG CTGATGAAGA TCCTGAACGC GCTGGTGCAG     780

ATGATGCAGC AAGGCGGCCT CGGCGGCGGC AACCAGGCGC AGGGCGGCTC GAAGGGTGCC     840

GGCAACGCCT CGCCGGCTTC CGGCGCGAAC CCGGGCGCGA ACCAGCCCGG TTCGGCGGAT     900

GATCAATCGT CCGGCCAGAA CAATCTGCAA TCCCAGATCA TGGATGTGGT GAAGGAGGTC     960

GTCCAGATCC TGCAGCAGAT GCTGGCGGCG CAGAACGGCG GCAGCCAGCA GTCCACCTCG    1020

ACGCAGCCGA TGTAA                                                     1035
```

Further information regarding the hypersensitive response elicitor polypeptide or protein derived from *Pseudomonas solanacearum* is set forth in Arlat, M., F. Van Gijsegem, J. C. Huet, J. C. Pemollet, and C. A. Boucher, "PopA1, a Protein which Induces a Hypersensitive-like Response in Specific Petunia Genotypes, is Secreted via the Hrp Pathway of *Pseudomonas solanacearum*," EMBO J. 13:543-533 (1994), which is hereby incorporated by reference.

Please replace the paragraph beginning on page 30, line 12, and ending on page 30, line 25, with the following replacement paragraph:

The hypersensitive response elicitor polypeptide or protein from *Xanthomonas campestris* pv. glycines has an amino acid sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 37 as follows:

```
Thr Leu Ile Glu Leu Met Ile Val Val Ala Ile Ile Ala Ile Leu Ala
1               5                   10                  15

Ala Ile Ala Leu Pro Ala Tyr Gln Asp Tyr
            20                  25
```

This sequence is an amino terminal sequence having only 26 residues from the hypersensitive response elicitor polypeptide or protein of *Xanthomonas campestris* pv. glycines. It matches with fimbrial subunit proteins determined in other *Xanthomonas campestris* pathovars.

Please replace the paragraph beginning on page 30, line 26, and ending on page 30, line 34, with the following replacement paragraph:

The hypersensitive response elicitor polypeptide or protein from *Xanthomonas campestris pv. pelargonii* is heat stable, protease sensitive, and has a molecular weight of 20 kDa. It includes an amino acid sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 38 as follows:

```
Ser Ser Gln Gln Ser Pro Ser Ala Gly Ser Glu Gln Gln Leu Asp Gln
1               5                   10                  15

Leu Leu Ala Met
            20
```

Please replace the paragraph beginning on page 32, line 27, and ending on page 33, line 5, with the following replacement paragraph:

An example of suitable fragments of a hypersensitive response elicitor which do not elicit a hypersensitive response include fragments of the *Erwinia amylovora* hypersensitive response elicitor. Suitable fragments include a C-terminal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23, an N-terminal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23, or an internal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23. The C-terminal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23 can span the following amino acids of

[SEQ. ID. No.] SEQ ID NO: 23: 169 and 403, 210 and 403, 267 and 403, or 343 and 403. The internal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23 can span the following amino acids of [SEQ. ID. No.] SEQ ID NO: 23: 105 and 179, 137 and 166, 121 and 150, or 137 and 156. Other suitable fragments can be identified in accordance with the present invention.

Please replace the paragraph beginning on page 33, line 6, and ending on page 33, line 10, with the following replacement paragraph:

Another example of a useful fragment of a hypersensitive response elicitor which fragment does not itself elicit a hypersensitive response is the protein fragment containing amino acids 190 to 294 of the amino acid sequence ([SEQ. ID. No.] SEQ ID NO: 31) for the *Pseudomonas syringae* pv. *syringae* hypersensitive response elicitor. This fragment is useful in imparting disease resistance and enhancing plant growth.

Please replace the paragraph beginning on page 33, line 11, and ending on page 33, line 14, with the following replacement paragraph:

Yet another example of a useful fragment of a hypersensitive response elicitor is the peptide having an amino acid sequence corresponding to [SEQ. ID. No.] SEQ ID NO: 39. This peptide is derived from the hypersensitive response eliciting glycoprotein of *Phytophthora megasperma* and enhances plant growth.

Please replace the paragraph beginning on page 46, line 29, and ending on page 47, line 12, with the following replacement paragraph:

Escherichia coli BL21(DE3) strains containing the hrpN clones were grown in Luria broth medium (5g/L Difco Yeast extract, 10 g/L Difco Tryptone, 5 g/L NaCl, and 1 mM NaOH) containing 30 μg/ml of kanamycin at 37°C overnight. The bacteria were then inoculated into 100 volumes of the same medium and grown at 37°C to an OD_{620} of 0.6-0.8.

The bacteria were then inoculated into 250 volumes of the same medium and grown at 37°C to an OD_{620} of ca. 0.3 or 0.6-0.8. One milli molar IPTG was then added and the cultures grown at 19°C overnight (ca. 18 hours). Not all of the clones were successfully expressed using this strategy. Several of the clones had to be grown in Terrific broth (12 g/L Bacto Tryptone, 24 g/L Bacto yeast, 0.4% glycerol, 0.17 M KH_2PO_4, and 0.72 K_2HPO_4), and/or grown at 37°C after IPTG induction, and/or harvested earlier than overnight (Table 1).

Table 1: Expression of hypersensitive response elicitor truncated proteins

Fragment	amino acids ([SEQ. ID. No.] SEQ ID NO: 23)	Growth medium	Induction O.D.	Expression temp.	Harvest time
1 (+ control)	1-403	LB	ca. 0.3 or 0.6-0.8	19°C or 25°C	16-18 hr
2 (+ control)	-	LB and TB	ca. 0.3 or 0.6-0.8	19 C and 37 C	16-18 hr
3	105-403	LB	0.6-0.8	19°C	16-18 hr
4	169-403	TB	ca. 0.3	19°C	16-18 hr
5	210-403	LB or M9ZB	0.6-0.8	19°C	16-18 hr
6	257-403	LB or M9ZB	0.6-0.8	19°C	16-18 hr
7	343-403	LB	ca. 0.3	19°C	5 hr
8	1-75	TB	ca. 0.3	37°C	16-18 hr
9	1-104	TB	ca. 0.3	37°C	16-18 hr
10	1-168	TB	ca. 0.3	37°C	16-18 hr
11	1-266	LB	ca. 0.3	37°C	4 hr
12	1-342	LB	0.6-0.8	19°C	16-18 hr
13	76-209	LB	ca. 0.3	37°C	5 hr
14	76-168	TB or LB	ca. 0.3	37°C	3 hr or 16-18 hr
15	105-209	M9ZB	ca. 0.3	37°C	3 hr
16	169-209	no expression			
17	105-168	LB	ca. 0.3	37°C	3-5 hr
18	99-209	LB	ca. 0.3	37°C	3 hr
19	137-204	LB	ca. 0.3	37°C	3 hr
20	137-180	LB	ca. 0.3	37°C	16-18 hr.
21	105-180	LB	ca. 0.3	37°C	3 hr
22	150-209	no expression			
23	150-180	no expression			

Please replace the paragraph beginning on page 51, line 2, and ending on page 52, line 2, with the following replacement paragraph:

The small scale expression and purification of the fragment proteins was done to screen for expression and HR activity (Table 2).

Table 2

Expression and HR activity of hypersensitive response elicitor truncated proteins (small scale screening)

Fragment #	Amino Acids ([SEQ. ID. No.] SEQ ID NO: 23)	Expression	HR activity
1(+control)	1-403	+	+
2(- control)	-	background protein only	-
3	105-403	+	+
4	169-403	+	-
5	210-403	+	-
6	267-403	+	-
7	343-403	+/-	-
8	1-75	+	-
9	1-104	+	+/-
10	1-168	+	+
11	1-266	+	+
12	1-342	+	+
13	76-209	+	+
14	76-168	+	-
15	105-209	+	+
16	169-209	-	-
17	105-168	+	-
18	99-209	+	+
19	137-204	+	+
20	137-180	+	+
21	105-180	+	+
22	150-209	-	-
23	150-180	-	-

All of the cloned fragment proteins were expressed at varying levels except for three small fragments (amino acids 169-209, 150-209, and 150-180). Fragments 210-403 and 267-403 were expressed very well, yielding a high concentration of protein from a small scale purification, resulting in a substantial protein band on SDS gel electrophoresis. Other fragments (such as a.a. 1-168 and 1-104) produced much less protein, resulting in faint protein bands upon electrophoresis. It was difficult to determine whether fragment 343-403,

the smallest C-terminal protein, was expressed, as there were several background proteins apparent on the gel, in addition to the suspected 343-403 protein. The positive and negative control proteins, consisting of the full length hypersensitive response elicitor protein and only background proteins, respectively, were tested for expression and HR activity as well.

Please replace the paragraph beginning on page 52, line 3, and ending on page 53, line 2, with the following replacement paragraph:

The large scale expression and purification of the fragment proteins was done to determine the level of expression and titer of the HR activity (Table 3).

Table 3

Expression level and HR titer of hypersensitive response elicitor truncated proteins (large sale purification)

Fragment #	Amino acids ([SEQ. ID. No.] SEQ ID NO: 23)	Expression	HR titer
1(+ control)	1-403	3.7 mg/ml	5-7 μg/ml
2 (- control)	-	-	1:2 dilution
4	169-403	2 mg/ml	-
5	210-403	5 mg/ml	-
6	267-403	4 mg/ml	-
7	343-402	200μg/ml	-
8	1-75	50μg/ml	-
9	1-104	50μg/ml	3 μg/ml (1:16 dilution)
10	1-168	1 mg/ml	1 μg/ml
13	76-209	2.5 mg/ml	5 μg/ml
14	76-168	2 mg/ml	-
15	105-209	5 mg/ml	5-10μg/ml
17	105-168	250μg/ml	-
19	137-204	3.6 mg/ml	3.5 μg/ml
20	137-180	250 μg/ml	16 μg/ml

The truncated proteins deemed to be the most important in characterizing the hypersensitive response elicitor were chosen for large scale expression. The positive control (full length hypersensitive response elicitor) was expressed at a relatively high level at 3.7 mg/ml. All of the C-terminal proteins were expressed at relatively high levels from 2-5 mg/ml, except for

fragment 343-403 as discussed earlier. The N-terminal fragments were expressed very well also; however, during the purification process, the protein precipitated and very little was resolubilized. The concentrations in Table 3 reflect only the solubilized protein. The internal fragments were expressed in the range of 2-3.6 mg/ml. It was extremely difficult to determine the concentration of fragment 105-168 (it was suspected that the concentration was much higher than indicated), as the protein bands on the SDS gel were large, but poorly stained. The negative control contained several background proteins as expected, but no obviously induced dominant protein.

Please replace the paragraph beginning on page 53, line 14, and ending on page 53, line 26, with the following replacement paragraph:

One definitive domain encompassing a small internal region of the protein from a.a. 137-180 ([SEQ. ID. No.] SEQ ID NO: 23), a mere 44 a.a, is identified as the smallest HR domain. The other potential HR domain is thought to be located in the N-terminus of the protein from a.a. 1-104 (possibly a.a. 1-75) ([SEQ. ID. No.] SEQ ID NO: 23). It was difficult to confirm or narrow down the N-terminus HR domain due to the difficulties encountered in purifying these fragment proteins. The N-terminus fragment proteins had to be purified with urea as no protein was recovered when the native purification process was used. Consequently, these proteins precipitated during the renaturing process and were difficult or nearly impossible to get back into solution, thereby making it hard to run the proteins through the HR assay, as only soluble protein is able to elicit HR. Difficulty narrowing the N-terminus HR domain was only compounded by the fact that the negative control elicited false HR at the low dilution levels thereby reducing the sensitivity of the assay.

Please replace the paragraph beginning on page 53, line 27, and ending on page 53, line 33, with the following replacement paragraph:

Surprisingly, when the internal HR domain was cleaved between a.a. 168 and 169 (fragments 76-168 and 105-168) ([SEQ. ID. No.] SEQ ID NO: 23) the fragment lost its

HR activity. This suggests that the HR activity of fragment 1-168 ([SEQ. ID. No.] SEQ ID NO: 23) should not be attributed to the internal HR domain, but rather to some other domain, leading to the assumption that there was likely a second HR domain to be found in the N-terminal region of the protein. However, as discussed earlier it was difficult to confirm this assumption.

Please replace the paragraph beginning on page 54, line 1, and ending on page 54, line 6, with the following replacement paragraph:

The hypersensitive response elicitor C-terminus (a.a. 210-403 ([SEQ. ID. No.] SEQ ID NO: 23)) did not contain an HR domain. It did not elicit HR at a detectable level using the current HR assay. Even the large C-terminal fragment from a.a. 169-403 ([SEQ. ID. No.] SEQ ID NO: 23) did not elicit HR even though it contained part of the internal HR domain. As stated above, cleaving the protein between amino acids 168 and 169 ([SEQ. ID. No.] SEQ ID NO: 23) causes a loss of HR activity.

Please replace the paragraph beginning on page 54, line 7, and ending on page 54, line 18, with the following replacement paragraph:

Because some of the small cloned proteins with 61 a.a. or less were not expressed, several oligopeptides were synthesized with 30 a.a. to narrow down the functional region of the internal HR domain. The oligopeptides were synthesized within the range of a.a. 121-179 ([SEQ. ID. No.] SEQ ID NO: 23). However, these oligos did not elicit HR. It was not expected that there would be an HR from oligos 137-166, 121-150, and 137-156 ([SEQ. ID. No.] SEQ ID NO: 23) as these fragments did not contain the imperative amino acids 168 and 169 ([SEQ. ID. No.] SEQ ID NO: 23). It was expected that the oligo 150-179 ([SEQ. ID. No.] SEQ ID NO: 23) would elicit an HR. It is possible that 30 a.a. is too small for the protein to elicit any activity due to a lack of folding and, therefore, a lack of binding or that during the synthesis of the peptides important amino acids were missed (either in the process, or simply by the choice of which 30 amino acids to synthesize) and, therefore, the fragments would not be able to elicit HR.

Appendix A

Version With Markings to Show Changes Made

Please replace the paragraph beginning on page 59, line 19, and ending on page 60, line 2, with the following replacement paragraph:

To test if the 13 amino acid peptide derived from the 42 kDa protein also enhanced plant growth, 20 mg of the oligopeptide was synthesized from Biosynthesis Corp. The synthesized sequence of the peptide is NH2-Val-Trp-Asn-Gln-Pro-Val-Arg-Gly-Phe-Lys-Val-Tyr-Glu-COOH ([SEQ. ID. No.] SEQ ID NO: 39). The synthesized peptide was resuspended in 10 ml of 5 mM potassium phosphate buffer and, then, diluted to 1 and 100 ng/ml with the same buffer. About 100 tomato seeds (variety, Marglobe) were submerged in 20 ml of peptide solution overnight. The soaked seeds were planted in an 8 inch pot with artificial soil. Seeds soaked in the buffer without the peptide were used as a control. After seedlings emerged and the first two true leaves fully expanded, the height of the tomato seedlings was recorded. The peptide was not able to elicit the HR in tobacco and other tested plants. However, it had a profound effect on plant growth promotion. Table 9 shows that tomato seedlings treated with the peptide increased 12.6 % in height, indicating that the fungal peptide derived from the 42 kDa glycroprotein can promote tomato seedling growth. Extended studies showed that the peptide also had similar growth effect in other crops including tobacco. Similar growth promotion effects were achieved by plants sprayed with the peptide solution.

In the Claims:

Claims 1, 2, 4-7, 9, 30, 33, and 36 have been amended as follows:

1. (Amended) An isolated fragment of a hypersensitive response elicitor protein or polypeptide, wherein said fragment does not elicit a hypersensitive response but has other activity in plants, said other activity comprising imparting disease resistance, enhancing plant growth, and/or controlling insects.

Appendix A

Version With Markings to Show Changes Made

2. (Amended) An isolated fragment according to claim 1, wherein the hypersensitive response elicitor protein or polypeptide is derived from an *Erwinia*, *Pseudomonas, Xanthomonas*, or *Phytophthora*.

4. (Amended) An isolated fragment according to claim 3, wherein the fragment is selected from the group consisting of a C-terminal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23, an N-terminal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23, and an internal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23.

5. (Amended) An isolated fragment according to claim 4, wherein the fragment is a C-terminal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23 spanning the following amino acids of [SEQ. ID. No.] SEQ ID NO: 23: 169 and 403, 210 and 403, 267 and 403, or 343 and 403.

6. (Amended) An isolated fragment according to claim 4, wherein the fragment is an N-terminal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23.

7. (Amended) An isolated fragment according to claim 4, wherein the fragment is an internal fragment of the amino acid sequence of [SEQ. ID. No.] SEQ ID NO: 23 spanning the following amino acids of [SEQ. ID. No.] SEQ ID NO: 23: 105 and 179, 137 and 166, 121 and 150, or 137 and 156.

9. (Amended) An isolated fragment according to claim 8, wherein the fragment contains amino acids 190 to 294 of [SEQ. ID. No.] SEQ ID NO: 31.

30. (Amended) A method of imparting disease resistance to plants comprising:

applying a fragment of a hypersensitive response elicitor protein or polypeptide[, which fragment does not elicit a hypersensitive response,] in a non-infectious

form to a plant or plant seed under conditions effective to impart disease resistance, wherein the fragment imparts disease resistance but does not elicit a hypersensitive response.

33. (Amended) A method of enhancing plant growth comprising:

applying a fragment of a hypersensitive response elicitor protein or polypeptide[, which fragment does not elicit a hypersensitive response,] in a non-infectious form to a plant or plant seed under conditions effective to enhance plant growth, wherein the fragment enhances plant growth but does not elicit a hypersensitive response.

36. (Amended) A method of insect control for plants comprising:

applying a fragment of a hypersensitive response elicitor protein or polypeptide[, which fragment does not elicit a hypersensitive response,] in a non-infectious form to a plant or plant seed under conditions effective to control insects, wherein the fragment controls insects but does not elicit a hypersensitive response.